0001493152-22-013802.txt : 20220516 0001493152-22-013802.hdr.sgml : 20220516 20220516161613 ACCESSION NUMBER: 0001493152-22-013802 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUANTRX BIOMEDICAL CORP CENTRAL INDEX KEY: 0000820608 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330202574 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-17119 FILM NUMBER: 22929266 BUSINESS ADDRESS: STREET 1: P.O. BOX 4960 CITY: TUALATIN STATE: OR ZIP: 97062 BUSINESS PHONE: 267-880-1595 MAIL ADDRESS: STREET 1: P.O. BOX 4960 CITY: TUALATIN STATE: OR ZIP: 97062 FORMER COMPANY: FORMER CONFORMED NAME: AFEM MEDICAL CORP DATE OF NAME CHANGE: 19970722 FORMER COMPANY: FORMER CONFORMED NAME: XTRAMEDICS INC /NV/ DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm
0000820608 false Q1 --12-31 0000820608 2022-01-01 2022-03-31 0000820608 2022-05-16 0000820608 2022-03-31 0000820608 2021-12-31 0000820608 us-gaap:SeriesBPreferredStockMember 2022-03-31 0000820608 us-gaap:SeriesBPreferredStockMember 2021-12-31 0000820608 2021-01-01 2021-03-31 0000820608 2020-12-31 0000820608 2021-03-31 0000820608 us-gaap:PreferredStockMember 2020-12-31 0000820608 us-gaap:CommonStockMember 2020-12-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000820608 QTXB:StockToBeIssuedMember 2020-12-31 0000820608 us-gaap:RetainedEarningsMember 2020-12-31 0000820608 us-gaap:PreferredStockMember 2021-12-31 0000820608 us-gaap:CommonStockMember 2021-12-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000820608 QTXB:StockToBeIssuedMember 2021-12-31 0000820608 us-gaap:RetainedEarningsMember 2021-12-31 0000820608 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000820608 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000820608 QTXB:StockToBeIssuedMember 2021-01-01 2021-03-31 0000820608 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000820608 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000820608 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000820608 QTXB:StockToBeIssuedMember 2022-01-01 2022-03-31 0000820608 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000820608 us-gaap:PreferredStockMember 2021-03-31 0000820608 us-gaap:CommonStockMember 2021-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000820608 QTXB:StockToBeIssuedMember 2021-03-31 0000820608 us-gaap:RetainedEarningsMember 2021-03-31 0000820608 us-gaap:PreferredStockMember 2022-03-31 0000820608 us-gaap:CommonStockMember 2022-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000820608 QTXB:StockToBeIssuedMember 2022-03-31 0000820608 us-gaap:RetainedEarningsMember 2022-03-31 0000820608 us-gaap:WarrantMember 2022-03-31 0000820608 us-gaap:WarrantMember 2021-03-31 0000820608 QTXB:SeriesBConvertiblePreferredStockMember 2022-03-31 0000820608 QTXB:SeriesBConvertiblePreferredStockMember 2021-03-31 0000820608 QTXB:DateRangesMember 2014-01-01 2017-12-31 0000820608 srt:MinimumMember 2017-12-31 0000820608 srt:MaximumMember 2017-12-31 0000820608 QTXB:MrAbramsMember 2022-03-31 0000820608 QTXB:MrAbramsMember 2021-12-31 0000820608 QTXB:MrAbramsMember srt:MinimumMember 2022-03-31 0000820608 QTXB:MrAbramsMember srt:MaximumMember 2022-03-31 0000820608 srt:ChiefExecutiveOfficerMember 2018-11-01 2018-11-30 0000820608 srt:DirectorMember 2018-11-01 2018-11-30 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-07-01 2017-08-31 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-08-31 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-01-01 2017-12-31 0000820608 us-gaap:SeriesBPreferredStockMember 2018-04-01 2018-04-30 0000820608 us-gaap:StockOptionMember 2022-03-31 0000820608 us-gaap:SubsequentEventMember 2022-04-11 2022-04-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File No. 000-17119

 

QUANTRX BIOMEDICAL CORPORATION
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   33-0202574

(State or Other Jurisdiction

of Incorporation or Organization)

  

(I.R.S. Employer

Identification Number)

 

10190 SW 90th Avenue, Tualatin, Oregon 97062
(Address of Principal Executive Offices) (Zip Code)
 
(212) 980-2235
(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-Accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Securities registered pursuant to Section 12(g) of the Exchange Act: Common Stock, par value $0.01 per share

 

The number of shares outstanding of the issuer’s common stock as of May 16, 2022 was 78,696,461.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  PAGE
PART I - FINANCIAL INFORMATION
   
ITEM 1. Financial Statements 4
     
  Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021 4
     
  Statements of Operations (Unaudited) for the three months ended March 31, 2022 and 2021 5
     
  Statements of Cash Flows (Unaudited) for the three months ended March 31, 2022 and 2021 6
     
  Quarterly Statements of Stockholders Equity (Unaudited) for the three months ended March 31, 2022 and 2021 7
     
  Condensed Notes to (Unaudited) Financial Statements 8
     
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
     
ITEM 4. Controls and Procedures 16
     
PART II - OTHER INFORMATION
   
ITEM 1. Legal Proceedings 17
     
ITEM 1A. Risk Factors 17
     
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
     
ITEM 3. Defaults Upon Senior Securities 17
     
ITEM 4. Mine Safety Disclosures 17
     
ITEM 5. Other Information 17
     
ITEM 6. Exhibits 17
     
Signatures 18

 

2

 

 

PART I – FINANCIAL INFORMATION

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

 

THIS QUARTERLY REPORT ON FORM 10-Q, INCLUDING EXHIBITS HERETO, CONTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THESE FORWARD-LOOKING STATEMENTS ARE TYPICALLY IDENTIFIED BY THE WORDS “ANTICIPATES,” “BELIEVES,” “EXPECTS,” “INTENDS,” “FORECASTS,” “PLANS,” “ESTIMATES,” “MAY,” “FUTURE,” “STRATEGY,” OR WORDS OF SIMILAR MEANING. VARIOUS FACTORS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED IN THE FORWARD-LOOKING STATEMENTS, INCLUDING THOSE DESCRIBED IN “RISK FACTORS” IN OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2021. WE ASSUME NO OBLIGATIONS TO UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT NEW INFORMATION, ACTUAL RESULTS, CHANGES IN ASSUMPTIONS, OR CHANGES IN OTHER FACTORS, EXCEPT AS REQUIRED BY LAW.

 

3

 

 

ITEM 1. Financial Statements

 

QUANTRX BIOMEDICAL CORPORATION

BALANCE SHEETS

 

     1     1 
   March 31,   December 31, 
   2022   2021 
   (Unaudited)    (Audited) 
ASSETS          
Current Assets:          
Cash and cash equivalents  $5,920   $5,950 
Total Current Assets   5,920    5,950 
Total Assets  $5,920   $5,950 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current Liabilities:          
Accounts payable  $13,795   $10,219 
Notes Payable   1,387,694    1,387,694 
Notes Payable, accrued interest   1,117,726    1,067,644 
Notes Payable, related party and accrued interest   185,289    181,490 
Total Liabilities   2,704,504    2,647,047 
           
Commitments and Contingencies   -    - 
           
Stockholders’ Equity (Deficit):          
Preferred stock; $0.01 par value, 25,000,000 authorized shares; 20,500,000 shares designated as Series B Convertible Preferred Stock; Series B Convertible Preferred shares 6,196,893 issued and outstanding   61,969    61,969 
Common stock; $0.01 par value; 150,000,000 authorized; 78,696,461 shares issued and outstanding   786,964    786,964 
Stock to be issued   8,600    8,600 
Additional paid-in capital   48,876,398    48,876,398 
Accumulated deficit   (52,432,515)   (52,375,028)
Total Stockholders’ Equity (Deficit)   (2,698,584)   (2,641,097)
           
Total Liabilities and Stockholders’ Equity (Deficit)  $5,920   $5,950 

 

The accompanying condensed notes are an integral part of these financial statements.

 

4

 

 

QUANTRX BIOMEDICAL CORPORATION

STATEMENTS OF OPERATIONS

(unaudited)

 

     2022     2021 
  

For the Three Months Ended

March 31,

 
   2022   2021 
Costs and Operating Expense:          
Sales, general and administrative  $3,606   $3,547 
Professional fees   -    1,500 
Total Costs and Operating Expenses   3,606    5,047 
           
LOSS FROM OPERATIONS:   (3,606)   (5,047)
           
Other Income (Expense):          
Interest Expense   (53,881)   (53,951)
Total Other Income (Expense), net   (53,881)   (53,951)
           
Profit (Loss) Before Taxes   (57,487)   (58,998)
           
Provision for Income Taxes   -    - 
           
Net Profit (Loss)  $(57,487)  $(58,998)
           
Basic and Diluted Net Loss per Common Share  $(0.00)  $(0.00)
           
Basic and Diluted Weighted Average Shares Used in per Share Calculation   78,696,461    78,696,461 

 

The accompanying condensed notes are an integral part of these interim financial statements.

 

5

 

 

QUANTRX BIOMEDICAL CORPORATION

STATEMENTS OF CASH FLOWS

(unaudited)

 

     2022     2021 
   For the Three Months Ended 
   March 31, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(57,487)  $(58,998)
Adjustments to reconcile net loss to net cash used by operating activities:          
(Increase) Decrease in:          
Increase (Decrease) in:          
Accounts Payable   3,576    (1,886)
Accrued interest   53,881    53,951 
Net Cash Used by Operating Activities   (30)   (6,933)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Net Cash Provided by Investing Activities   -    - 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Net Cash Provided (Used) by Financing Activities   -    - 
           
Net Decrease in Cash and Cash Equivalents   (30)   (6,933)
           
Cash and Cash Equivalents, Beginning of Period   5,950    55,428 
           
Cash and Cash Equivalents, End of Period  $5,920   $48,495 
           
Supplemental Cash Flow Disclosures:          
Interest expense paid in cash  $-   $- 
Income tax paid  $-   $- 

 

The accompanying condensed notes are an integral part of these interim financial statements.

 

6

 

 

QUANTRX BIOMEDICAL CORPORATION

STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited)

 

   Number of Shares   Amount   Number of Shares   Amount   Paid-in Capital   to be Issued   Accumulated Deficit     Total 
   Preferred Stock   Common Stock   Additional   Stock         
   Number of Shares   Amount   Number of Shares   Amount   Paid-in Capital   to be Issued   Accumulated Deficit   Total 
For the three months ended March 31, 2021                                        
BALANCE, January 1, 2021   6,196,893   $61,969    78,696,461   $786,964   $48,876,398   $8,600   $(52,114,986)  $(2,381,055)
                                         
Net loss for the three months ended March 31, 2021   -    -    -    -    -    -    (58,998)   (58,998)
BALANCE, MARCH 31, 2021   6,196,893   $61,969    78,696,461   $786,964   $48,876,398   $8,600   $(52,173,984)  $(2,440,053)
 For the three months ended March 31, 2022                                        
BALANCE, January 1, 2022   6,196,893   $61,969    78,696,461   $786,964   $48,876,398   $8,600   $(52,375,028)  $(2,641,097)
                                         
Net loss for the three months ended March 31, 2022   -    -    -    -    -    -    (57,487)   (57,487)
BALANCE, MARCH 31, 2022   6,196,893   $61,969    78,696,461   $786,964   $48,876,398   $8,600   $(52,432,515)  $(2,698,584)

 

The accompanying condensed notes are an integral part of these interim financial statements

 

7

 

 

QUANTRX BIOMEDICAL CORPORATION

CONDENSED NOTES TO FINANCIAL STATEMENTS

(unaudited)

 

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Overview

 

As used in this Quarterly Report on Form 10-Q, the terms “Company”, “we”, “our”, “us”, “QuantRx” or the “Company” refers to QuantRx Biomedical Corporation, unless context otherwise requires. QuantRx Biomedical Corporation was incorporated on December 5, 1986, in the State of Nevada. Our principal business office is located at 10190 SW 90th Avenue, Tualatin, Oregon 97062.

 

We have developed and intend to commercialize our patented miniform pads (“PADs”) and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs. We are also developing and intend to commercialize genomic diagnostics for the laboratory market, based on our lateral flow patents. Our platforms include: inSync®, UniqueTM, and OEM branded over-the-counter and laboratory testing products based on our core intellectual property related to our PAD technology.

 

The continuation of our operations remains contingent upon the receipt of additional financing required to execute our business and operating plan, which is currently focused on the commercialization of our PAD technology either directly or through a joint venture or other relationship intended to increase shareholder value. In the interim, we have nominal operations, focused principally on maintaining our intellectual property portfolio and maintaining compliance with the public company reporting requirements. In order to continue as a going concern, we will need to raise capital, which may include through the issuance of debt and/or equity securities. No assurances can be given that we will be able to obtain additional financing under terms favorable to us, if at all, or otherwise successfully develop a business and operating plan or enter into an alternative relationship to commercialize our PAD technology.

 

Our principal business line consists of over-the-counter commercialization of our InSync feminine hygienic interlabial pad, the Unique® Miniform for hemorrhoid application, and other treated miniforms (the “OTC Business”), as well as maintaining established and continuing licensing relationships related to these products. We also own certain diagnostic testing technology (the “Diagnostic Business”, and collectively with the OTC Business, the “Business”) that is based on our lateral flow patents. Management believes this corporate structure permits us to more efficiently explore options to maximize the value of our products and intellectual property portfolio, with the objective of maximizing the value of the Businesses for the benefit of the Company and our shareholders.

 

Our current focus is to obtain additional working capital necessary to continue as a going concern, and to develop a longer term financing and operating plan to: (i) commercialize our over-the-counter products either directly or through joint ventures, mergers or similar transactions intended to capitalize on potential commercial opportunities; (ii) contract manufacturing of our over-the-counter products to third parties while maintaining control over the manufacturing process; (iii) maintain our intellectual property portfolio with respect to patents and licenses pertaining to both the OTC Business and the Diagnostics Business; and (iv) maximize the value of our investments in non-core assets. As a result of our current financial condition, however, our efforts in the short-term will be focused on obtaining financing necessary to maintain the Company as a going concern.

 

We follow the accounting guidance outlined in the Financial Accounting Standards Board (“FASB”) Codification guidelines. The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted principles for interim financial information and with the items under Regulation S-X required by the instructions to Form 10-Q. They may not include all information and footnotes required by United States Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2022. The interim unaudited financial statements presented herein should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, which unless otherwise disclosed herein, consisting primarily of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders’ equity.

 

8

 

 

2. MANAGEMENT STATEMENT REGARDING GOING CONCERN

 

We currently are not generating revenue from operations, and do not anticipate generating meaningful revenue from operations or otherwise in the short-term. We have historically financed our operations primarily through issuances of equity and the proceeds from the issuance of promissory notes. In the past, we also provided for our cash needs by issuing our common stock, par value $0.01 per share (“Common Stock”), options and warrants for certain operating costs, including consulting and professional fees, as well as divesting its minority equity interests and equity-linked investments.

 

Our history of operating losses, limited cash resources and the absence of an operating plan necessary to capitalize on our assets raise substantial doubt about our ability to continue as a going concern absent a strengthening of our cash position. Management is currently pursuing various funding options, including seeking debt or equity financing, licensing opportunities and the sale of certain investment holdings, as well as a strategic, merger or other transaction to obtain additional funding to continue the development of, and to successfully commercialize, our products. There can be no assurance that the Company will be successful in its efforts. Should we be unable to obtain adequate financing or generate sufficient revenue in the future, the Company’s business, result of operations, liquidity and financial condition would be materially and adversely harmed, and we will be unable to continue as a going concern.

 

There can be no assurance that, assuming we are able to strengthen its cash position, we will achieve sufficient revenue or profitable operations to continue as a going concern.

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements.

 

Accounting for Share-Based Payments. The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“Topic 718”),, which establishes the accounting for transactions in which an entity exchanges equity securities for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company uses the Black-Scholes option pricing model in determining fair value. Accordingly, compensation cost has been recognized using the fair value method and expected term accrual requirements as prescribed. During the three months ended March 31, 2022 and 2021, the Company had no stock compensation expense.

 

In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“2018-07”) to expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted for an “emerging growth company” beginning after December 15, 2019. The Company has adopted this standard effective from January 1, 2020 and the adoption of this standard did not have any significant impact on the unaudited condensed consolidated interim financial statements.

 

9

 

 

In the case of modifications, the Black-Scholes model is used to value modified warrants on the modification date by applying the revised assumptions. The difference between the fair value of the warrants prior to the modification and after the modification determines the incremental value. In the past, the Company has modified warrants in connection with the issuance of certain notes and note extensions. These modified warrants were originally issued in connection with previous private placement investments. In the case of debt issuances, the warrants were accounted for as original issuance discount based on their relative fair values. When modified in connection with a note issuance, the Company recognizes the incremental value as a part of the debt discount calculation, using its relative fair value in accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”. When modified in connection with note extensions, the Company recognized the incremental value as prepaid interest, which is expensed over the term of the extension.

 

The fair value of each share-based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year. During the three months ended March 31, 2022 and 2021, the Company did not make any Black-Scholes model assumptions, as no share-based payments were made during those periods.

 

Risk-Free Interest Rate. The interest rate used is based on the yield of a U.S. Treasury security as of the beginning of the year.

 

Expected Volatility. The Company calculates the expected volatility based on historical volatility of monthly stock prices over a three-year period.

 

Dividend Yield. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.

 

Expected Term. For options, the Company has no history of employee exercise patterns. Therefore, the Company uses the option term as the expected term. For warrants, the Company uses the actual term of the warrant.

 

Pre-Vesting Forfeitures. Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

 

Earnings per Share. The Company computes net income (loss) per common share in accordance with ASC Topic 260, “Earnings Per Share” (“Topic 260”). Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

For the three months ended March 31, 2022 and the three months ended March 31, 2021, basic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been antidilutive.

 

As of March 31, 2022 and at March 31, 2021, the Company had outstanding warrants exercisable for 15,000,000 shares of Common Stock, and outstanding preferred stock, $0.01 par value (“Preferred Stock”) convertible into 6,196,893 shares of its Common Stock, which options, warrants and Preferred Stock were deemed to be antidilutive for the three months ended March 31, 2022 and March 31, 2021. At March 31, 2022 and March 31, 2021, the Company had reserved for issuance to certain investors 860,000 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (“Series B Preferred”), convertible into 860,000 shares of its Common Stock. As of March 31, 2022 and at March 31, 2021, the Company has estimated and reserved for issuance approximately 20.0 million shares of Common Stock for a future conversion of its issued and outstanding Bridge Notes (See Note 4).

 

10

 

 

Fair Value. The Company has adopted ASC Topic 820, “Fair Value Measurements and Disclosures” for both financial and nonfinancial assets and liabilities. The Company has not elected the fair value option for any of its assets or liabilities.

 

Use of Estimates. The accompanying financial statements are prepared in conformity with GAAP, and include certain estimates and assumptions, which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting period. Accordingly, actual results may differ from those estimates.

 

Reclassifications. Prior period financial statement amounts have been reclassified to conform to current period presentation. The reclassifications have no effect on net loss or earnings per share.

 

Recent Accounting Pronouncements.

 

Management has considered all recent accounting pronouncements in the current period and identified no pronouncements that would have an impact on our financial statements.

 

4. CONVERTIBLE NOTES PAYABLE

 

During the years 2014 to 2017, the Company issued a series of Bridge Notes (the “Bridge Notes”) in aggregate principal amount of $1,489,694. The Bridge Notes matured on various dates through 2018. The Bridge Notes are in default and bear interest rates ranging from 12% to 18%. As of March 31, 2022, the Bridge Notes are due and payable.

 

At March 31, 2022 and December 31, 2021, the Company’s Convertible Notes Payable are as follows:

 

  

March 31,

2022

   December 31, 2021 
Notes Payable  $1,387,694   $1,387,694 
Accrued Interest  $1,117,726   $1,067,644 
Notes Payable, related party  $102,000   $102,000 
Accrued Interest, related Party  $83,289   $79,490 
Total Notes Payable  $2,690,709   $2,636,828 

 

Notes Payable, Related Party.

 

As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $185,289 and $181,490, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes. The Bridge Notes held by Mr. Abrams are in default and bear interest rates ranging from 12% to 18%. As of March 31, 2022, the Bridge Notes are due and payable.

 

5. RELATED PARTY TRANSACTIONS

 

In November 2018, the Company authorized payment of $3,500 per month to Dr. Hirschman for his services as Chief Executive Officer and $3,500 to Mr. Abrams for his services as a Director. Effective January 1, 2020, Mr. Abrams has waived the payments of fees for his services. Effective April 1, 2020, Dr. Hirschman has waived the payment of is fees as Chief Executive Officer.

 

As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $185,289 and $181,490, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes.

 

11

 

 

6. PREFERRED STOCK

 

The Company has authorized 25,000,000 shares of Preferred Stock, of which 20,500,000 are designated as Series B Preferred, with a stated value of approximately $204,000 (“Series B Preferred”). The remaining authorized shares of Preferred Stock had not been designated by the Company as of March 31, 2022.

 

Series B Convertible Preferred Stock

 

The Series B Preferred ranks senior to the Company’s Common Stock for purposes of liquidation preference, and to all other classes and series of equity securities of the Company that by their terms did not rank senior to the Series B Preferred (“Junior Stock”). Holders of the Series B Preferred are entitled to receive cash dividends, when, as and if declared by the Board of Directors, and they shall be entitled to receive an amount equal to the cash dividend declared on one share of Common Stock multiplied by the number of shares of Common Stock equal to the outstanding shares of Series B Preferred, on an as converted basis. The holders of Series B Preferred have voting rights to vote as a class on matters (a) amending, altering or repealing the provisions of the Series B Preferred so as to adversely affect any right, preference, privilege or voting power of the Series B Preferred; or (b) to affect any distribution with respect to Junior Stock. At any time, the holders of Series B Preferred may, subject to limitations, elect to convert all or any portion of their Series B Preferred into fully paid non-assessable shares of the Company’s Common Stock at a 1:1 conversion rate.

 

In July and August, 2017, the Company entered into Note Purchase Agreements with two existing stockholders, pursuant to which the Company issued certain Bridge Notes (the “2017 Bridge Notes”) in the aggregate principal amount of $86,000. As additional consideration for the purchase of the 2017 Bridge Notes, the Company has reserved for issuance an aggregate of 860,000 shares of Series B Preferred to be issued to the purchasers of the 2017 Bridge Notes. The Company has valued the Series B Preferred and has recorded a discount on the 2017 Bridge Notes of $7,818, which was amortized in full during the year ended December 31, 2017.

 

In April 2018, the Company completed the purchase of 10,480,049 shares of Series B Preferred from an institutional shareholder for an aggregate purchase price of $20,000. Following this transaction, the shareholder no longer holds shares in the Company.

 

As of March 31, 2022 and December 31, 2021, the Company had 6,196,893 shares of Series B Preferred issued and outstanding, with a liquidation preference of $61,969 and convertible into 6,196,893 shares of the Company’s Common Stock.

 

7. COMMON STOCK, OPTIONS AND WARRANTS

 

The Company has authorized 150,000,000 shares of its Common Stock for issuance, of which 78,696,461 were issued and outstanding at each March 31, 2022 and December 31, 2021.

 

During the three months ended March 31, 2022 and March 31, 2021, there were no warrants issued by the Company. As of March 31, 2022, the Company has one warrant issued and outstanding, this warrant was issued in December 2018 to Preprogen’s designee to purchase up to 15.0 million shares of the Company’s Common Stock, at an exercise price of $0.05 per share. The warrant was exercisable immediately upon issuance, and expires on December 14, 2022.

 

2007 Incentive and Non-Qualified Stock Option Plan. The fair value of options granted under the Company’s 2007 Incentive and Non-Qualified Stock Option Plan is recorded as compensation expense over the vesting period, or, for performance based awards, the expected service term. The Company did not issue any options during the three months ended March 31, 2022 or 2021. As of March 31, 2022, the Company has no options issued and outstanding.

 

8. SUBSEQUENT EVENTS

 

On April 12, 2022, the Company received a shareholder loan in the amount of $25,000.

 

12

 

 

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition should be read in conjunction with the financial statements and notes to financial statements included elsewhere in this filing. The following discussion (as well as statements in Item 1 above and elsewhere) contains forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 that involve risks and uncertainties. Some or all of the results anticipated by these forward-looking statements may not occur. Forward-looking statements involve known and unknown risks and uncertainties including, but not limited to, trends in the biotechnology, healthcare, and pharmaceutical sectors of the economy; competitive pressures and technological developments from domestic and foreign genetic research and development organizations which may affect the nature and potential viability of our business strategy; and private or public sector demand for products and services similar to what we plan to commercialize. We disclaim any intention or obligation to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

 

Unless otherwise indicated or the context otherwise requires, all references in this report to “we”, “our”, “us”, the “Company” or similar terms refer to QuantRx Biomedical Corporation, a Nevada corporation.

 

Overview

 

We have developed and intend to commercialize our patented miniform pad (“PAD”) and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs. We are also developing and intend to commercialize genomic diagnostics for the laboratory market, based on our lateral flow patents. Our platforms include: inSync®, UniqueTM, and OEM branded over-the-counter and laboratory testing products based on our core intellectual property related to our PAD technology.

 

The continuation of our operations remains contingent upon the receipt of additional financing required to execute our business and operating plan, which is currently focused on the commercialization of our PAD technology, either directly or through a joint venture or other relationship intended to increase shareholder value. In the interim, we have nominal operations, focused principally on maintaining our intellectual property portfolio and maintaining compliance with the public company reporting requirements. In order to continue as a going concern, we will need to raise capital, which may include through the issuance of debt and/or equity securities. No assurances can be given that we will be able to obtain additional financing under terms favorable to us, if at all, or otherwise successfully develop a business and operating plan or enter into an alternative relationship to commercialize our PAD technology.

 

Our principal business line consists of over-the-counter commercialization of our InSync feminine hygienic interlabial pad, the Unique® Miniform for hemorrhoid application, and other treated miniforms (the “OTC Business”), as well as maintaining established and continuing licensing relationships related to the OTC Business. We also own certain diagnostic testing technology that is based on our lateral flow patents (the “Diagnostic Business”, and collectively with the OTC Business, the “Business”). Management believes this corporate structure permits us to more efficiently explore options to maximize the value of the Business, with the objective of maximizing the value of the Business for the benefit of the Company and our shareholders.

 

Our current focus is to obtain additional working capital necessary to continue as a going concern, and to develop a longer term financing and operating plan to: (i) commercialize our over-the-counter products either directly or through joint ventures, mergers or similar transactions intended to capitalize on potential commercial opportunities; (ii) contract manufacturing of our over-the-counter products to third parties while maintaining control over the manufacturing process; (iii) maintain our intellectual property portfolio with respect to patents and licenses pertaining to both the OTC Business and the Diagnostics Business; and (iv) maximize the value of our investments in non-core assets. As a result of our current financial condition, however, our efforts in the short-term will be focused on obtaining financing necessary to maintain the Company as a going concern.

 

While we expect the impacts of COVID-19 to have an adverse effect on our ability to successfully obtain working capital necessary to continue as a going concern and to develop a longer term financing and operating plan, we are unable to predict the extent or nature of these impacts at this time.

 

13

 

 

The following discussion of our financial condition should be read together with our financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2022.

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2022 to the Three Months Ended March 31, 2021.

 

The Company did not generate any revenue during the three months ended March 31, 2022 or the three months ended March 31, 2021. The absence of revenue is due to no royalty revenue attributable to the Company’s PAD technology received during the periods. Management does not anticipate that the Company will generate any revenue until such time as the Company develops a plan to commercialize its over-the-counter products, which is contingent on the receipt of financing.

 

Sales, general and administrative expense for the three months ended March 31, 2022 and 2021 was $3,606 and $3,547, respectively. Sales, general and administrative expense includes, but is not limited to, consulting expense, office and insurance expense, accounting and other costs to maintain compliance with the Company’s SEC reporting requirements. The increase in sales, general and administrative expense for the three months ended March 31, 2022 is principally due to higher costs for the Company’s transfer agent, partially offset by lower costs for maintenance of intellectual property.

 

Professional fees for the three months ended March 31, 2022 and 2021 were $0 and $1,500, respectively. Professional fees include the costs of legal, consulting and auditing services provided to us. The decrease in professional fees for the three months ended March 31, 2022 is principally due to higher legal fees paid in the 2021 period.

 

The Company did not incur any research and development costs during the three months ended March 31, 2022 or 2021. The Company does not expect to engage in any research and development activity until funding is secured and it develops a plan to commercialize its products.

 

Interest expense for the three months ended March 31, 2022 and 2021 was $53,881 and $53,951, respectively. The decrease in interest expense in the 2022 period compared to the 2021 period is slightly lower due to timing.

 

During the three months ended March 31, 2022, the Company recorded net loss of $57,487 compared to net loss for the three months ended March 31, 2021 of $58,998. The decrease in net loss during the 2022 period is primarily due lower expenses during the 2022 period, as discussed above.

 

The Company expects net loss to decrease in future periods due to the current suspension of its active operations and its lack of revenue. The Company does not expect to re-commence active operations until it is able to secure financing necessary to execute its business and operating plan, including the development and launch of its OTC Business, or to otherwise capitalize on our PAD technology.

 

Liquidity and Capital Resources

 

At March 31, 2022, the Company had cash and cash equivalents of $5,920 as compared to $5,950 at December 31, 2021.

 

The Company had cash and cash equivalents of $48,495 at March 31, 2021. The decrease in cash and cash equivalents between the corresponding 2022 and 2021 periods of approximately $42,575 is primarily attributable to cash used for operations in the 2021 and 2022 periods.

 

During the three months ended March 31, 2022, the Company used $30 for operating activities, compared to $6,933 used during the three months ended March 31, 2021. The net overall decrease in cash used for operating activities during the three months ended March 31, 2021 is attributable primarily to decreased operating expenses in the 2022 period.

 

14

 

 

The Company has not generated sufficient revenue from operations to meet its operating expense. The Company requires additional funding to complete the development and launch of its OTC Business, or to otherwise capitalize on its PAD technology. The Company has historically financed its operations primarily through issuances of equity and the proceeds of debt instruments. In the past, the Company has also provided for its cash needs by issuing shares of its Common Stock, options and warrants for certain operating costs, including consulting and professional fees.

 

Management believes that given the current economic environment and the continuing need to strengthen our cash position, there is substantial doubt about our ability to continue as a going concern. We are pursuing various funding options, including licensing opportunities and the sale of investment holdings, as well other financing transactions, to obtain additional funding to continue the development of our products and bring them to commercial markets. There can be no assurance that we will be successful in our efforts. Should we be unable to raise adequate financing or generate sufficient revenue in the future, the Company’s business, results of operations, liquidity and financial condition would be materially and adversely harmed.

 

The Company believes that the ability of the Company to re-commence operations, and therefore continue as a going concern is dependent upon its ability to do any or all of the following:

 

  ● obtain adequate sources of funding to pay operating expense and fund long-term business operations;
     
  ● enter into a licensing or other relationship that allows the Company to commercialize its products;
     
  ● manage or control working capital requirements by reducing operating expense; and
     
  ● develop new, and enhance existing, relationships with product distributors and other points of distribution for the Company’s products.

 

There can be no assurance that the Company will be successful in achieving its short- or long-term plans as set forth above, or that such plans, if consummated, will enable the Company to obtain profitable operations or continue in the long-term as a going concern.

 

Off-Balance Sheet Arrangements

 

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

 

Critical Accounting Policies

 

The listing below is not intended to be a comprehensive list of all of our accounting policies. In most cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States. In addition to the listing below accounting policies listed below, please See to Note 3 to the Financial Statements.

 

Impairment of Assets

 

We assess the impairment of long-lived assets, including our other intangible assets, at least annually or whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The determination of related estimated useful lives and whether or not these assets are impaired involves significant judgments, related primarily to the future profitability and/or future value of the assets. Changes in our strategic plan and/or market conditions could significantly impact these judgments and could require adjustments to recorded asset balances. We hold investments in companies having operations or technologies in areas which are within or adjacent to our strategic focus when acquired, all of which are privately held and whose values are difficult to determine. We record an investment impairment charge if we believe an investment has experienced a decline in value that is other than temporary. Future changes in our strategic direction, adverse changes in market conditions or poor operating results of underlying investments could result in losses or an inability to recover the carrying value of the investments that may not be reflected in an investment’s current carrying value, thereby possibly requiring an impairment charge in the future.

 

15

 

 

In determining fair value of assets, the Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets that are not readily apparent from other sources. Actual fair value may differ from management estimates resulting in potential impairments causing material changes to certain assets and results of operations.

 

Genomics USA, Inc. (“GUSA”): During the years ended December 31, 2018 and 2017, the Company had recorded losses of $0 and $169,948, respectively, on an impairment on the value of its Common Stock investment in GUSA. The Company has valued the impairment based on the dilution of the Company’s investment and certain other factors. As of December 31, 2018, the Company has fully impaired its investment in GUSA.

 

Global Cancer Diagnostics, Inc. (“GCD”): During 2015, the Company entered into a letter of intent with GCD, which provided for, among other things, the advance payment of $50,000 towards a potential business combination. During 2017, the Company determined the full amount of the advanced payment to be impaired.

 

Preprogen LLC (“Preprogen): During the years ended December 31, 2019 and December 31, 2018, the Company recorded a loss of $222,000 and $278,000, respectively, on an impairment on the value of its investment in Preprogen. The Company has valued the impairment based on an evaluation by a third-party using the value of similar investments in comparable companies. The Company has fully impaired its investment in Preprogen.

 

Deferred Taxes

 

We recognize deferred tax assets and liabilities based on differences between the financial statement carrying amounts and tax bases of assets and liabilities, which requires management to perform estimates of future transactions and their respective valuations. We review our deferred tax assets for recoverability and establish a valuation allowance if it is more likely than not that the Company will not realize the benefit of the net deferred tax asset. At March 31, 2022 and December 31, 2021, a valuation allowance has been established. The likelihood of a material change in the valuation allowance depends on our ability to generate sufficient future taxable income. In the future, if management determines that the likelihood exists to utilize the Company’s deferred tax assets, a reduction of the valuation allowance could materially increase the Company’s net deferred tax asset.

 

ITEM 4. Controls and Procedures

 

(a) Evaluation of disclosure controls and procedures.

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of March 31, 2022. Based on this evaluation, and in light of the previously disclosed material weaknesses in internal controls over financial reporting, the Company’s Chief Executive Officer, who also serves as its principal financial officer, concluded that our disclosure controls and procedures were not effective.

 

(b) Changes in internal controls over financial reporting.

 

There has been no change in our internal control over financial reporting that occurred during our most recent fiscal year that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There has been no progress towards remediating our previously disclosed material weakness due to the lack of funding.

 

16

 

 

PART II - OTHER INFORMATION

 

ITEM 1. Legal Proceedings

 

As of the date hereof, there are no material pending legal proceedings to which we are a party to or of which any of our property is the subject.

 

ITEM 1A. Risk Factors

 

Our results of operations and financial condition are subject to numerous risks and uncertainties described in our Annual Report on Form 10-K for our fiscal year ended December 31, 2021, filed on April 15, 2022. You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report on Form 10-Q. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted. As of March 31, 2022, there have been no material changes to the disclosures made in the above-referenced Form 10-K.

 

ITEM 2. Unregistered Sales of Equity Securities, and Use of Proceeds

 

None.

 

ITEM 3. Defaults Upon Senior Securities

 

None.

 

ITEM 4. Mine Safety Disclosures

 

Not Applicable.

 

ITEM 5. Other Information

 

None.

 

ITEM 6. Exhibits

 

Exhibit   Description
31   Certification of Chief Executive Officer and Principal Financial and Accounting Officer required under Rule 13a-14(a) or Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended.
32   Certification of Chief Executive Officer and Principal Financial and Accounting Officer required under Rule 13a-14(a) or Rule 15d-14(a) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 16, 2022 /s/ Shalom Hirschman
  Shalom Hirschman
  Principal Executive, Financial and Accounting Officer

 

18

 

 EX-31 2 ex31.htm

 

Exhibit 31

 

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO

EXCHANGE ACT RULE 13A-14(A)

 

I, Shalom Hirschman, certify that:

 

1. I have reviewed this Quarterly report on Form 10-Q of QuantRx Biomedical Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 16, 2022 /s/ Shalom Hirschman
  Shalom Hirschman
  Principal Executive and Financial Officer

 

 

 

 

 EX-32 3 ex32.htm

 

Exhibit 32

 

CERTIFICATION PURSUANT TO 18 U.S.C. Sec.1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying Quarterly Report of QuantRx Biomedical Corporation (the “Company”) on Form 10-Q for the period ending March 31, 2022 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), the undersigned, Shalom Hirschman, Principal Executive and Principal Financial and Accounting Officer of the Company, certifies, to my best knowledge and belief, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: May 16, 2022 /s/ Shalom Hirschman
  Shalom Hirschman
  Principal Executive and Financial Officer

 

 

 EX-101.SCH 4 qtxb-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - PREFERRED STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 qtxb-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 qtxb-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 qtxb-20220331_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Stock to be Issued [Member] Retained Earnings [Member] Warrant [Member] Series B Convertible Preferred Stock [Member] Debt Instrument [Axis] Date Ranges [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Title of Individual [Axis] Mr. Abrams [Member] Chief Executive Officer [Member] Director [Member] Bridge Notes 2017 [Member] Derivative Instrument [Axis] Equity Option [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Total Current Assets Total Assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current Liabilities: Accounts payable Notes Payable Notes Payable, accrued interest Notes Payable, related party and accrued interest Total Liabilities Commitments and Contingencies Stockholders’ Equity (Deficit): Preferred stock; $0.01 par value, 25,000,000 authorized shares; 20,500,000 shares designated as Series B Convertible Preferred Stock; Series B Convertible Preferred shares 6,196,893 issued and outstanding Common stock; $0.01 par value; 150,000,000 authorized; 78,696,461 shares issued and outstanding Stock to be issued Additional paid-in capital Accumulated deficit Total Stockholders’ Equity (Deficit) Total Liabilities and Stockholders’ Equity (Deficit) Statement [Table] Statement [Line Items] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Costs and Operating Expense: Sales, general and administrative Professional fees Total Costs and Operating Expenses LOSS FROM OPERATIONS: Other Income (Expense): Interest Expense Total Other Income (Expense), net Profit (Loss) Before Taxes Provision for Income Taxes Net Profit (Loss) Basic and Diluted Net Loss per Common Share Basic and Diluted Weighted Average Shares Used in per Share Calculation Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used by operating activities: Increase (Decrease) in: Accounts Payable Accrued interest Net Cash Used by Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided (Used) by Financing Activities Net Decrease in Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Cash Flow Disclosures: Interest expense paid in cash Income tax paid Beginning balance, value Beginning balance, shares Ending balance, value Ending balance, shares Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements [Abstract] MANAGEMENT STATEMENT REGARDING GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] PREFERRED STOCK COMMON STOCK, OPTIONS AND WARRANTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Accounting for Share-Based Payments Earnings per Share Fair Value Use of Estimates Reclassifications Recent Accounting Pronouncements SCHEDULE OF CONVERTIBLE NOTES PAYABLE Date of incorporation State of incorporation Common stock, par or stated value per share Share based compensation expenses Share-based payment, dividend rate Outstanding warrants exercisable Preferred stock, par or stated value per share Conversion of shares converted Common stock reserved for issuance Accrued Interest Notes Payable, related party Accrued Interest, related Party Total Notes Payable Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Aggregate principal amount Interest rate Notes payable, related party and accrued interest Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Officers compensation Schedule of Stock by Class [Table] Class of Stock [Line Items] Capital units, value Debt conversion, description Debt instrument, periodic payment, principal Preferred stock, capital shares reserved for future issuance Amortization of debt discount premium Stock issued shares for purchase of assets Aggregate purchase price Preferred stock, liquidation preference, value Preferred stock convertible shares of common stock Offsetting Assets [Table] Offsetting Assets [Line Items] Warrants to purchase of common stock Warrants exercise price per share Warrants maturity date Subsequent Event [Table] Subsequent Event [Line Items] Proceeds from shareholder loan Notes payable related party and accrued interest current. Stock to be issued. Stock to be Issued [Member] Reclassifications [Policy Text Block] Date Ranges [Member] Interest rate. Accrued interest, related party, current. Bridge Notes 2017 [Member] Aggregate purchase price. Preferred stock purchased shares. Series B Convertible Preferred Stock [Member] Mr. Abrams [Member] Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Costs and Expenses Operating Income (Loss) Interest Expense Other Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding Notes Payable [Default Label] EX-101.PRE 8 qtxb-20220331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
 3 Months Ended
Mar. 31, 2022
May 16, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 000-17119  
Entity Registrant Name QUANTRX BIOMEDICAL CORPORATION  
Entity Central Index Key 0000820608  
Entity Tax Identification Number 33-0202574  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 10190 SW 90th Avenue  
Entity Address, City or Town Tualatin  
Entity Address, State or Province OR  
Entity Address, Postal Zip Code 97062  
City Area Code 212  
Local Phone Number 980-2235  
Entity Current Reporting Status Yes  
Entity Interactive Data Current No  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   78,696,461
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash and cash equivalents $ 5,920 $ 5,950
Total Current Assets 5,920 5,950
Total Assets 5,920 5,950
Current Liabilities:    
Accounts payable 13,795 10,219
Notes Payable 1,387,694 1,387,694
Notes Payable, accrued interest 1,117,726 1,067,644
Notes Payable, related party and accrued interest 185,289 181,490
Total Liabilities 2,704,504 2,647,047
Commitments and Contingencies
Stockholders’ Equity (Deficit):    
Preferred stock; $0.01 par value, 25,000,000 authorized shares; 20,500,000 shares designated as Series B Convertible Preferred Stock; Series B Convertible Preferred shares 6,196,893 issued and outstanding 61,969 61,969
Common stock; $0.01 par value; 150,000,000 authorized; 78,696,461 shares issued and outstanding 786,964 786,964
Stock to be issued 8,600 8,600
Additional paid-in capital 48,876,398 48,876,398
Accumulated deficit (52,432,515) (52,375,028)
Total Stockholders’ Equity (Deficit) (2,698,584) (2,641,097)
Total Liabilities and Stockholders’ Equity (Deficit) $ 5,920 $ 5,950
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 25,000,000 25,000,000
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 78,696,461 78,696,461
Common stock, shares outstanding 78,696,461 78,696,461
Series B Preferred Stock [Member]    
Preferred stock, shares authorized 20,500,000 20,500,000
Preferred stock, shares issued 6,196,893 6,196,893
Preferred stock, shares outstanding 6,196,893 6,196,893
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Costs and Operating Expense:    
Sales, general and administrative $ 3,606 $ 3,547
Professional fees 1,500
Total Costs and Operating Expenses 3,606 5,047
LOSS FROM OPERATIONS: (3,606) (5,047)
Other Income (Expense):    
Interest Expense (53,881) (53,951)
Total Other Income (Expense), net (53,881) (53,951)
Profit (Loss) Before Taxes (57,487) (58,998)
Provision for Income Taxes
Net Profit (Loss) $ (57,487) $ (58,998)
Basic and Diluted Net Loss per Common Share $ (0.00) $ (0.00)
Basic and Diluted Weighted Average Shares Used in per Share Calculation 78,696,461 78,696,461
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (57,487) $ (58,998)
Increase (Decrease) in:    
Accounts Payable 3,576 (1,886)
Accrued interest 53,881 53,951
Net Cash Used by Operating Activities (30) (6,933)
CASH FLOWS FROM INVESTING ACTIVITIES    
Net Cash Provided by Investing Activities
CASH FLOWS FROM FINANCING ACTIVITIES    
Net Cash Provided (Used) by Financing Activities
Net Decrease in Cash and Cash Equivalents (30) (6,933)
Cash and Cash Equivalents, Beginning of Period 5,950 55,428
Cash and Cash Equivalents, End of Period 5,920 48,495
Supplemental Cash Flow Disclosures:    
Interest expense paid in cash
Income tax paid
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock to be Issued [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 61,969 $ 786,964 $ 48,876,398 $ 8,600 $ (52,114,986) $ (2,381,055)
Beginning balance, shares at Dec. 31, 2020 6,196,893 78,696,461        
Net loss (58,998) (58,998)
Ending balance, value at Mar. 31, 2021 $ 61,969 $ 786,964 48,876,398 8,600 (52,173,984) (2,440,053)
Ending balance, shares at Mar. 31, 2021 6,196,893 78,696,461        
Beginning balance, value at Dec. 31, 2021 $ 61,969 $ 786,964 48,876,398 8,600 (52,375,028) (2,641,097)
Beginning balance, shares at Dec. 31, 2021 6,196,893 78,696,461        
Net loss (57,487) (57,487)
Ending balance, value at Mar. 31, 2022 $ 61,969 $ 786,964 $ 48,876,398 $ 8,600 $ (52,432,515) $ (2,698,584)
Ending balance, shares at Mar. 31, 2022 6,196,893 78,696,461        
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.22.1
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Overview

 

As used in this Quarterly Report on Form 10-Q, the terms “Company”, “we”, “our”, “us”, “QuantRx” or the “Company” refers to QuantRx Biomedical Corporation, unless context otherwise requires. QuantRx Biomedical Corporation was incorporated on December 5, 1986, in the State of Nevada. Our principal business office is located at 10190 SW 90th Avenue, Tualatin, Oregon 97062.

 

We have developed and intend to commercialize our patented miniform pads (“PADs”) and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs. We are also developing and intend to commercialize genomic diagnostics for the laboratory market, based on our lateral flow patents. Our platforms include: inSync®, UniqueTM, and OEM branded over-the-counter and laboratory testing products based on our core intellectual property related to our PAD technology.

 

The continuation of our operations remains contingent upon the receipt of additional financing required to execute our business and operating plan, which is currently focused on the commercialization of our PAD technology either directly or through a joint venture or other relationship intended to increase shareholder value. In the interim, we have nominal operations, focused principally on maintaining our intellectual property portfolio and maintaining compliance with the public company reporting requirements. In order to continue as a going concern, we will need to raise capital, which may include through the issuance of debt and/or equity securities. No assurances can be given that we will be able to obtain additional financing under terms favorable to us, if at all, or otherwise successfully develop a business and operating plan or enter into an alternative relationship to commercialize our PAD technology.

 

Our principal business line consists of over-the-counter commercialization of our InSync feminine hygienic interlabial pad, the Unique® Miniform for hemorrhoid application, and other treated miniforms (the “OTC Business”), as well as maintaining established and continuing licensing relationships related to these products. We also own certain diagnostic testing technology (the “Diagnostic Business”, and collectively with the OTC Business, the “Business”) that is based on our lateral flow patents. Management believes this corporate structure permits us to more efficiently explore options to maximize the value of our products and intellectual property portfolio, with the objective of maximizing the value of the Businesses for the benefit of the Company and our shareholders.

 

Our current focus is to obtain additional working capital necessary to continue as a going concern, and to develop a longer term financing and operating plan to: (i) commercialize our over-the-counter products either directly or through joint ventures, mergers or similar transactions intended to capitalize on potential commercial opportunities; (ii) contract manufacturing of our over-the-counter products to third parties while maintaining control over the manufacturing process; (iii) maintain our intellectual property portfolio with respect to patents and licenses pertaining to both the OTC Business and the Diagnostics Business; and (iv) maximize the value of our investments in non-core assets. As a result of our current financial condition, however, our efforts in the short-term will be focused on obtaining financing necessary to maintain the Company as a going concern.

 

We follow the accounting guidance outlined in the Financial Accounting Standards Board (“FASB”) Codification guidelines. The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted principles for interim financial information and with the items under Regulation S-X required by the instructions to Form 10-Q. They may not include all information and footnotes required by United States Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2022. The interim unaudited financial statements presented herein should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, which unless otherwise disclosed herein, consisting primarily of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.

 

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders’ equity.

 

 
XML 16 R8.htm IDEA: XBRL DOCUMENT v3.22.1
MANAGEMENT STATEMENT REGARDING GOING CONCERN
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
MANAGEMENT STATEMENT REGARDING GOING CONCERN

2. MANAGEMENT STATEMENT REGARDING GOING CONCERN

 

We currently are not generating revenue from operations, and do not anticipate generating meaningful revenue from operations or otherwise in the short-term. We have historically financed our operations primarily through issuances of equity and the proceeds from the issuance of promissory notes. In the past, we also provided for our cash needs by issuing our common stock, par value $0.01 per share (“Common Stock”), options and warrants for certain operating costs, including consulting and professional fees, as well as divesting its minority equity interests and equity-linked investments.

 

Our history of operating losses, limited cash resources and the absence of an operating plan necessary to capitalize on our assets raise substantial doubt about our ability to continue as a going concern absent a strengthening of our cash position. Management is currently pursuing various funding options, including seeking debt or equity financing, licensing opportunities and the sale of certain investment holdings, as well as a strategic, merger or other transaction to obtain additional funding to continue the development of, and to successfully commercialize, our products. There can be no assurance that the Company will be successful in its efforts. Should we be unable to obtain adequate financing or generate sufficient revenue in the future, the Company’s business, result of operations, liquidity and financial condition would be materially and adversely harmed, and we will be unable to continue as a going concern.

 

There can be no assurance that, assuming we are able to strengthen its cash position, we will achieve sufficient revenue or profitable operations to continue as a going concern.

 
XML 17 R9.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements.

 

Accounting for Share-Based Payments. The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“Topic 718”),, which establishes the accounting for transactions in which an entity exchanges equity securities for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company uses the Black-Scholes option pricing model in determining fair value. Accordingly, compensation cost has been recognized using the fair value method and expected term accrual requirements as prescribed. During the three months ended March 31, 2022 and 2021, the Company had no stock compensation expense.

 

In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“2018-07”) to expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted for an “emerging growth company” beginning after December 15, 2019. The Company has adopted this standard effective from January 1, 2020 and the adoption of this standard did not have any significant impact on the unaudited condensed consolidated interim financial statements.

 

 

In the case of modifications, the Black-Scholes model is used to value modified warrants on the modification date by applying the revised assumptions. The difference between the fair value of the warrants prior to the modification and after the modification determines the incremental value. In the past, the Company has modified warrants in connection with the issuance of certain notes and note extensions. These modified warrants were originally issued in connection with previous private placement investments. In the case of debt issuances, the warrants were accounted for as original issuance discount based on their relative fair values. When modified in connection with a note issuance, the Company recognizes the incremental value as a part of the debt discount calculation, using its relative fair value in accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”. When modified in connection with note extensions, the Company recognized the incremental value as prepaid interest, which is expensed over the term of the extension.

 

The fair value of each share-based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year. During the three months ended March 31, 2022 and 2021, the Company did not make any Black-Scholes model assumptions, as no share-based payments were made during those periods.

 

Risk-Free Interest Rate. The interest rate used is based on the yield of a U.S. Treasury security as of the beginning of the year.

 

Expected Volatility. The Company calculates the expected volatility based on historical volatility of monthly stock prices over a three-year period.

 

Dividend Yield. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.

 

Expected Term. For options, the Company has no history of employee exercise patterns. Therefore, the Company uses the option term as the expected term. For warrants, the Company uses the actual term of the warrant.

 

Pre-Vesting Forfeitures. Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

 

Earnings per Share. The Company computes net income (loss) per common share in accordance with ASC Topic 260, “Earnings Per Share” (“Topic 260”). Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

For the three months ended March 31, 2022 and the three months ended March 31, 2021, basic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been antidilutive.

 

As of March 31, 2022 and at March 31, 2021, the Company had outstanding warrants exercisable for 15,000,000 shares of Common Stock, and outstanding preferred stock, $0.01 par value (“Preferred Stock”) convertible into 6,196,893 shares of its Common Stock, which options, warrants and Preferred Stock were deemed to be antidilutive for the three months ended March 31, 2022 and March 31, 2021. At March 31, 2022 and March 31, 2021, the Company had reserved for issuance to certain investors 860,000 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (“Series B Preferred”), convertible into 860,000 shares of its Common Stock. As of March 31, 2022 and at March 31, 2021, the Company has estimated and reserved for issuance approximately 20.0 million shares of Common Stock for a future conversion of its issued and outstanding Bridge Notes (See Note 4).

 

 

Fair Value. The Company has adopted ASC Topic 820, “Fair Value Measurements and Disclosures” for both financial and nonfinancial assets and liabilities. The Company has not elected the fair value option for any of its assets or liabilities.

 

Use of Estimates. The accompanying financial statements are prepared in conformity with GAAP, and include certain estimates and assumptions, which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting period. Accordingly, actual results may differ from those estimates.

 

Reclassifications. Prior period financial statement amounts have been reclassified to conform to current period presentation. The reclassifications have no effect on net loss or earnings per share.

 

Recent Accounting Pronouncements.

 

Management has considered all recent accounting pronouncements in the current period and identified no pronouncements that would have an impact on our financial statements.

 
XML 18 R10.htm IDEA: XBRL DOCUMENT v3.22.1
CONVERTIBLE NOTES PAYABLE
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
CONVERTIBLE NOTES PAYABLE

4. CONVERTIBLE NOTES PAYABLE

 

During the years 2014 to 2017, the Company issued a series of Bridge Notes (the “Bridge Notes”) in aggregate principal amount of $1,489,694. The Bridge Notes matured on various dates through 2018. The Bridge Notes are in default and bear interest rates ranging from 12% to 18%. As of March 31, 2022, the Bridge Notes are due and payable.

 

At March 31, 2022 and December 31, 2021, the Company’s Convertible Notes Payable are as follows:

 

  

March 31,

2022

   December 31, 2021 
Notes Payable  $1,387,694   $1,387,694 
Accrued Interest  $1,117,726   $1,067,644 
Notes Payable, related party  $102,000   $102,000 
Accrued Interest, related Party  $83,289   $79,490 
Total Notes Payable  $2,690,709   $2,636,828 

 

Notes Payable, Related Party.

 

As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $185,289 and $181,490, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes. The Bridge Notes held by Mr. Abrams are in default and bear interest rates ranging from 12% to 18%. As of March 31, 2022, the Bridge Notes are due and payable.

 
XML 19 R11.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS
 3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

5. RELATED PARTY TRANSACTIONS

 

In November 2018, the Company authorized payment of $3,500 per month to Dr. Hirschman for his services as Chief Executive Officer and $3,500 to Mr. Abrams for his services as a Director. Effective January 1, 2020, Mr. Abrams has waived the payments of fees for his services. Effective April 1, 2020, Dr. Hirschman has waived the payment of is fees as Chief Executive Officer.

 

As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $185,289 and $181,490, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes.

 

 
XML 20 R12.htm IDEA: XBRL DOCUMENT v3.22.1
PREFERRED STOCK
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
PREFERRED STOCK

6. PREFERRED STOCK

 

The Company has authorized 25,000,000 shares of Preferred Stock, of which 20,500,000 are designated as Series B Preferred, with a stated value of approximately $204,000 (“Series B Preferred”). The remaining authorized shares of Preferred Stock had not been designated by the Company as of March 31, 2022.

 

Series B Convertible Preferred Stock

 

The Series B Preferred ranks senior to the Company’s Common Stock for purposes of liquidation preference, and to all other classes and series of equity securities of the Company that by their terms did not rank senior to the Series B Preferred (“Junior Stock”). Holders of the Series B Preferred are entitled to receive cash dividends, when, as and if declared by the Board of Directors, and they shall be entitled to receive an amount equal to the cash dividend declared on one share of Common Stock multiplied by the number of shares of Common Stock equal to the outstanding shares of Series B Preferred, on an as converted basis. The holders of Series B Preferred have voting rights to vote as a class on matters (a) amending, altering or repealing the provisions of the Series B Preferred so as to adversely affect any right, preference, privilege or voting power of the Series B Preferred; or (b) to affect any distribution with respect to Junior Stock. At any time, the holders of Series B Preferred may, subject to limitations, elect to convert all or any portion of their Series B Preferred into fully paid non-assessable shares of the Company’s Common Stock at a 1:1 conversion rate.

 

In July and August, 2017, the Company entered into Note Purchase Agreements with two existing stockholders, pursuant to which the Company issued certain Bridge Notes (the “2017 Bridge Notes”) in the aggregate principal amount of $86,000. As additional consideration for the purchase of the 2017 Bridge Notes, the Company has reserved for issuance an aggregate of 860,000 shares of Series B Preferred to be issued to the purchasers of the 2017 Bridge Notes. The Company has valued the Series B Preferred and has recorded a discount on the 2017 Bridge Notes of $7,818, which was amortized in full during the year ended December 31, 2017.

 

In April 2018, the Company completed the purchase of 10,480,049 shares of Series B Preferred from an institutional shareholder for an aggregate purchase price of $20,000. Following this transaction, the shareholder no longer holds shares in the Company.

 

As of March 31, 2022 and December 31, 2021, the Company had 6,196,893 shares of Series B Preferred issued and outstanding, with a liquidation preference of $61,969 and convertible into 6,196,893 shares of the Company’s Common Stock.

 
XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.1
COMMON STOCK, OPTIONS AND WARRANTS
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
COMMON STOCK, OPTIONS AND WARRANTS

7. COMMON STOCK, OPTIONS AND WARRANTS

 

The Company has authorized 150,000,000 shares of its Common Stock for issuance, of which 78,696,461 were issued and outstanding at each March 31, 2022 and December 31, 2021.

 

During the three months ended March 31, 2022 and March 31, 2021, there were no warrants issued by the Company. As of March 31, 2022, the Company has one warrant issued and outstanding, this warrant was issued in December 2018 to Preprogen’s designee to purchase up to 15.0 million shares of the Company’s Common Stock, at an exercise price of $0.05 per share. The warrant was exercisable immediately upon issuance, and expires on December 14, 2022.

 

2007 Incentive and Non-Qualified Stock Option Plan. The fair value of options granted under the Company’s 2007 Incentive and Non-Qualified Stock Option Plan is recorded as compensation expense over the vesting period, or, for performance based awards, the expected service term. The Company did not issue any options during the three months ended March 31, 2022 or 2021. As of March 31, 2022, the Company has no options issued and outstanding.

 
XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

8. SUBSEQUENT EVENTS

 

On April 12, 2022, the Company received a shareholder loan in the amount of $25,000.
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Accounting for Share-Based Payments

Accounting for Share-Based Payments. The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“Topic 718”),, which establishes the accounting for transactions in which an entity exchanges equity securities for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company uses the Black-Scholes option pricing model in determining fair value. Accordingly, compensation cost has been recognized using the fair value method and expected term accrual requirements as prescribed. During the three months ended March 31, 2022 and 2021, the Company had no stock compensation expense.

 

In June 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“2018-07”) to expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted for an “emerging growth company” beginning after December 15, 2019. The Company has adopted this standard effective from January 1, 2020 and the adoption of this standard did not have any significant impact on the unaudited condensed consolidated interim financial statements.

 

 

In the case of modifications, the Black-Scholes model is used to value modified warrants on the modification date by applying the revised assumptions. The difference between the fair value of the warrants prior to the modification and after the modification determines the incremental value. In the past, the Company has modified warrants in connection with the issuance of certain notes and note extensions. These modified warrants were originally issued in connection with previous private placement investments. In the case of debt issuances, the warrants were accounted for as original issuance discount based on their relative fair values. When modified in connection with a note issuance, the Company recognizes the incremental value as a part of the debt discount calculation, using its relative fair value in accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”. When modified in connection with note extensions, the Company recognized the incremental value as prepaid interest, which is expensed over the term of the extension.

 

The fair value of each share-based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year. During the three months ended March 31, 2022 and 2021, the Company did not make any Black-Scholes model assumptions, as no share-based payments were made during those periods.

 

Risk-Free Interest Rate. The interest rate used is based on the yield of a U.S. Treasury security as of the beginning of the year.

 

Expected Volatility. The Company calculates the expected volatility based on historical volatility of monthly stock prices over a three-year period.

 

Dividend Yield. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.

 

Expected Term. For options, the Company has no history of employee exercise patterns. Therefore, the Company uses the option term as the expected term. For warrants, the Company uses the actual term of the warrant.

 

Pre-Vesting Forfeitures. Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

 
Earnings per Share

Earnings per Share. The Company computes net income (loss) per common share in accordance with ASC Topic 260, “Earnings Per Share” (“Topic 260”). Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

For the three months ended March 31, 2022 and the three months ended March 31, 2021, basic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been antidilutive.

 

As of March 31, 2022 and at March 31, 2021, the Company had outstanding warrants exercisable for 15,000,000 shares of Common Stock, and outstanding preferred stock, $0.01 par value (“Preferred Stock”) convertible into 6,196,893 shares of its Common Stock, which options, warrants and Preferred Stock were deemed to be antidilutive for the three months ended March 31, 2022 and March 31, 2021. At March 31, 2022 and March 31, 2021, the Company had reserved for issuance to certain investors 860,000 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (“Series B Preferred”), convertible into 860,000 shares of its Common Stock. As of March 31, 2022 and at March 31, 2021, the Company has estimated and reserved for issuance approximately 20.0 million shares of Common Stock for a future conversion of its issued and outstanding Bridge Notes (See Note 4).

 

 
Fair Value

Fair Value. The Company has adopted ASC Topic 820, “Fair Value Measurements and Disclosures” for both financial and nonfinancial assets and liabilities. The Company has not elected the fair value option for any of its assets or liabilities.

 
Use of Estimates

Use of Estimates. The accompanying financial statements are prepared in conformity with GAAP, and include certain estimates and assumptions, which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting period. Accordingly, actual results may differ from those estimates.

 
Reclassifications

Reclassifications. Prior period financial statement amounts have been reclassified to conform to current period presentation. The reclassifications have no effect on net loss or earnings per share.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements.

 

Management has considered all recent accounting pronouncements in the current period and identified no pronouncements that would have an impact on our financial statements.
XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.1
CONVERTIBLE NOTES PAYABLE (Tables)
 3 Months Ended
Mar. 31, 2022
Debt Disclosure [Abstract]  
SCHEDULE OF CONVERTIBLE NOTES PAYABLE

At March 31, 2022 and December 31, 2021, the Company’s Convertible Notes Payable are as follows:

 

  

March 31,

2022

   December 31, 2021 
Notes Payable  $1,387,694   $1,387,694 
Accrued Interest  $1,117,726   $1,067,644 
Notes Payable, related party  $102,000   $102,000 
Accrued Interest, related Party  $83,289   $79,490 
Total Notes Payable  $2,690,709   $2,636,828 
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.22.1
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Date of incorporation Dec. 05, 1986
State of incorporation NV
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.22.1
MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Common stock, par or stated value per share $ 0.01 $ 0.01
XML 27 R19.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Share based compensation expenses $ 0 $ 0  
Share-based payment, dividend rate 0.00%    
Preferred stock, par or stated value per share $ 0.01   $ 0.01
Common stock reserved for issuance 20,000,000.0 20,000,000.0  
Series B Convertible Preferred Stock [Member]      
Preferred stock, par or stated value per share $ 0.01 $ 0.01  
Common stock reserved for issuance 860,000 860,000  
Warrant [Member]      
Outstanding warrants exercisable 15,000,000 15,000,000  
Preferred Stock [Member]      
Preferred stock, par or stated value per share $ 0.01 $ 0.01  
Conversion of shares converted 6,196,893 6,196,893  
Common Stock [Member]      
Conversion of shares converted 860,000 860,000  
XML 28 R20.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Notes Payable $ 1,387,694 $ 1,387,694
Accrued Interest 1,117,726 1,067,644
Notes Payable, related party 102,000 102,000
Accrued Interest, related Party 83,289 79,490
Total Notes Payable $ 2,690,709 $ 2,636,828
XML 29 R21.htm IDEA: XBRL DOCUMENT v3.22.1
CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)
 48 Months Ended
Dec. 31, 2017
Mar. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]      
Notes payable, related party and accrued interest   $ 185,289 $ 181,490
Mr. Abrams [Member]      
Short-Term Debt [Line Items]      
Notes payable, related party and accrued interest   $ 185,289 $ 181,490
Minimum [Member]      
Short-Term Debt [Line Items]      
Interest rate 12.00%    
Minimum [Member] | Mr. Abrams [Member]      
Short-Term Debt [Line Items]      
Interest rate   12.00%  
Maximum [Member]      
Short-Term Debt [Line Items]      
Interest rate 18.00%    
Maximum [Member] | Mr. Abrams [Member]      
Short-Term Debt [Line Items]      
Interest rate   18.00%  
Date Ranges [Member]      
Short-Term Debt [Line Items]      
Aggregate principal amount $ 1,489,694    
XML 30 R22.htm IDEA: XBRL DOCUMENT v3.22.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended
Nov. 30, 2018
Mar. 31, 2022
Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Notes payable, related party and accrued interest   $ 185,289 $ 181,490
Chief Executive Officer [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Officers compensation $ 3,500    
Director [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Officers compensation $ 3,500    
XML 31 R23.htm IDEA: XBRL DOCUMENT v3.22.1
PREFERRED STOCK (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2018
Aug. 31, 2017
Mar. 31, 2022
Dec. 31, 2017
Dec. 31, 2021
Class of Stock [Line Items]          
Preferred stock, shares authorized     25,000,000   25,000,000
Debt conversion, description     the Company’s Common Stock at a 1:1 conversion rate    
Bridge Notes 2017 [Member]          
Class of Stock [Line Items]          
Debt instrument, periodic payment, principal   $ 86,000      
Preferred stock, capital shares reserved for future issuance   860,000      
Amortization of debt discount premium       $ 7,818  
Series B Preferred Stock [Member]          
Class of Stock [Line Items]          
Preferred stock, shares authorized     20,500,000   20,500,000
Capital units, value     $ 204,000    
Stock issued shares for purchase of assets 10,480,049        
Aggregate purchase price $ 20,000        
Preferred stock, shares issued     6,196,893   6,196,893
Preferred stock, shares outstanding     6,196,893   6,196,893
Preferred stock, liquidation preference, value     $ 61,969   $ 61,969
Preferred stock convertible shares of common stock     6,196,893   6,196,893
XML 32 R24.htm IDEA: XBRL DOCUMENT v3.22.1
COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Offsetting Assets [Line Items]    
Common stock, shares authorized 150,000,000 150,000,000
Common stock, shares issued 78,696,461 78,696,461
Common stock, shares outstanding 78,696,461 78,696,461
Warrants to purchase of common stock 15,000,000.0  
Warrants exercise price per share $ 0.05  
Warrants maturity date Dec. 14, 2022  
Equity Option [Member]    
Offsetting Assets [Line Items]    
Common stock, shares issued 0  
Common stock, shares outstanding 0  
XML 33 R25.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details Narrative)
Apr. 12, 2022
USD ($)
Subsequent Event [Member]  
Subsequent Event [Line Items]  
Proceeds from shareholder loan $ 25,000
XML 34 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000820608 2022-01-01 2022-03-31 0000820608 2022-05-16 0000820608 2022-03-31 0000820608 2021-12-31 0000820608 us-gaap:SeriesBPreferredStockMember 2022-03-31 0000820608 us-gaap:SeriesBPreferredStockMember 2021-12-31 0000820608 2021-01-01 2021-03-31 0000820608 2020-12-31 0000820608 2021-03-31 0000820608 us-gaap:PreferredStockMember 2020-12-31 0000820608 us-gaap:CommonStockMember 2020-12-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000820608 QTXB:StockToBeIssuedMember 2020-12-31 0000820608 us-gaap:RetainedEarningsMember 2020-12-31 0000820608 us-gaap:PreferredStockMember 2021-12-31 0000820608 us-gaap:CommonStockMember 2021-12-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000820608 QTXB:StockToBeIssuedMember 2021-12-31 0000820608 us-gaap:RetainedEarningsMember 2021-12-31 0000820608 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000820608 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000820608 QTXB:StockToBeIssuedMember 2021-01-01 2021-03-31 0000820608 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000820608 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000820608 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000820608 QTXB:StockToBeIssuedMember 2022-01-01 2022-03-31 0000820608 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000820608 us-gaap:PreferredStockMember 2021-03-31 0000820608 us-gaap:CommonStockMember 2021-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000820608 QTXB:StockToBeIssuedMember 2021-03-31 0000820608 us-gaap:RetainedEarningsMember 2021-03-31 0000820608 us-gaap:PreferredStockMember 2022-03-31 0000820608 us-gaap:CommonStockMember 2022-03-31 0000820608 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000820608 QTXB:StockToBeIssuedMember 2022-03-31 0000820608 us-gaap:RetainedEarningsMember 2022-03-31 0000820608 us-gaap:WarrantMember 2022-03-31 0000820608 us-gaap:WarrantMember 2021-03-31 0000820608 QTXB:SeriesBConvertiblePreferredStockMember 2022-03-31 0000820608 QTXB:SeriesBConvertiblePreferredStockMember 2021-03-31 0000820608 QTXB:DateRangesMember 2014-01-01 2017-12-31 0000820608 srt:MinimumMember 2017-12-31 0000820608 srt:MaximumMember 2017-12-31 0000820608 QTXB:MrAbramsMember 2022-03-31 0000820608 QTXB:MrAbramsMember 2021-12-31 0000820608 srt:MinimumMember QTXB:MrAbramsMember 2022-03-31 0000820608 srt:MaximumMember QTXB:MrAbramsMember 2022-03-31 0000820608 srt:ChiefExecutiveOfficerMember 2018-11-01 2018-11-30 0000820608 srt:DirectorMember 2018-11-01 2018-11-30 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-07-01 2017-08-31 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-08-31 0000820608 QTXB:BridgeNotesTwoZeroOneSevenMember 2017-01-01 2017-12-31 0000820608 us-gaap:SeriesBPreferredStockMember 2018-04-01 2018-04-30 0000820608 us-gaap:StockOptionMember 2022-03-31 0000820608 us-gaap:SubsequentEventMember 2022-04-11 2022-04-12 iso4217:USD shares iso4217:USD shares pure 0000820608 false Q1 --12-31 10-Q true 2022-03-31 2022 false 000-17119 QUANTRX BIOMEDICAL CORPORATION NV 33-0202574 10190 SW 90th Avenue Tualatin OR 97062 212 980-2235 Yes No Non-accelerated Filer true false false 78696461 5920 5920 5950 5950 5920 5920 5950 5950 5920 5920 5950 5950 13795 13795 10219 10219 1387694 1387694 1387694 1387694 1117726 1117726 1067644 1067644 185289 185289 181490 181490 2704504 2704504 2647047 2647047 0.01 0.01 25000000 25000000 20500000 20500000 6196893 6196893 6196893 6196893 61969 61969 61969 61969 0.01 0.01 150000000 150000000 78696461 78696461 78696461 78696461 786964 786964 786964 786964 8600 8600 8600 8600 48876398 48876398 48876398 48876398 -52432515 -52432515 -52375028 -52375028 -2698584 -2698584 -2641097 -2641097 5920 5920 5950 5950 3606 3547 1500 3606 5047 -3606 -5047 53881 53951 -53881 -53951 -57487 -58998 -57487 -58998 -0.00 -0.00 78696461 78696461 -57487 -58998 3576 -1886 53881 53951 -30 -6933 -30 -6933 5950 55428 5920 48495 6196893 61969 78696461 786964 48876398 8600 -52114986 -2381055 -58998 -58998 6196893 61969 78696461 786964 48876398 8600 -52173984 -2440053 6196893 61969 78696461 786964 48876398 8600 -52375028 -2641097 -57487 -57487 6196893 61969 78696461 786964 48876398 8600 -52432515 -2698584 <p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zi0su3AYlh2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82D_z8aMaMJCQnQ1">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As used in this Quarterly Report on Form 10-Q, the terms “<i>Company</i>”, “<i>we</i>”, “<i>our</i>”, “<i>us</i>”, “<i>QuantRx</i>” or the “<i>Company</i>” refers to QuantRx Biomedical Corporation, unless context otherwise requires. QuantRx Biomedical Corporation was incorporated on <span id="xdx_900_edei--EntityIncorporationDateOfIncorporation_dd_c20220101__20220331_zNBiLsJb7oTh" title="Date of incorporation">December 5, 1986</span>, in the State of <span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20220101__20220331_znUJ2PG2Gvzd" title="State of incorporation">Nevada</span>. Our principal business office is located at 10190 SW 90th Avenue, Tualatin, Oregon 97062.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We have developed and intend to commercialize our patented miniform pads (“<i>PADs</i>”) and PAD based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses and other medical needs. We are also developing and intend to commercialize genomic diagnostics for the laboratory market, based on our lateral flow patents. Our platforms include: inSync®, Unique</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TM<span style="background-color: white">, and OEM branded over-the-counter and laboratory testing products based on our core intellectual property related to our PAD technology.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The continuation of our operations remains contingent upon the receipt of additional financing required to execute our business and operating plan, which is currently focused on the commercialization of our PAD technology either directly or through a joint venture or other relationship intended to increase shareholder value. In the interim, we have nominal operations, focused principally on maintaining our intellectual property portfolio and maintaining compliance with the public company reporting requirements. In order to continue as a going concern, we will need to raise capital, which may include through the issuance of debt and/or equity securities. No assurances can be given that we will be able to obtain additional financing under terms favorable to us, if at all, or otherwise successfully develop a business and operating plan or enter into an alternative relationship to commercialize our PAD technology.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal business line consists of over-the-counter commercialization of our InSync feminine hygienic interlabial pad, the Unique® Miniform for hemorrhoid application, and other treated miniforms (the “<i>OTC Business</i>”), as well as maintaining established and continuing licensing relationships related to these products. We also own certain diagnostic testing technology (the “<i>Diagnostic Business</i>”, and collectively with the OTC Business, the “Business”) that is based on our lateral flow patents. Management believes this corporate structure permits us to more efficiently explore options to maximize the value of our products and intellectual property portfolio, with the objective of maximizing the value of the Businesses for the benefit of the Company and our shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current focus is to obtain additional working capital necessary to continue as a going concern, and to develop a longer term financing and operating plan to: (i) commercialize our over-the-counter products either directly or through joint ventures, mergers or similar transactions intended to capitalize on potential commercial opportunities; (ii) contract manufacturing of our over-the-counter products to third parties while maintaining control over the manufacturing process; (iii) maintain our intellectual property portfolio with respect to patents and licenses pertaining to both the OTC Business and the Diagnostics Business; and (iv) maximize the value of our investments in non-core assets. As a result of our current financial condition, however, our efforts in the short-term will be focused on obtaining financing necessary to maintain the Company as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We follow the accounting guidance outlined in the Financial Accounting Standards Board (“FASB”) Codification guidelines. The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted principles for interim financial information and with the items under Regulation S-X required by the instructions to Form 10-Q. They may not include all information and footnotes required by United States Generally Accepted Accounting Principles (“<i>GAAP</i>”) for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2022. The interim unaudited financial statements presented herein should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, which unless otherwise disclosed herein, consisting primarily of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1986-12-05 NV <p id="xdx_80F_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zBcamyGXJJ3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82B_zSNoDVZqUHEc">MANAGEMENT STATEMENT REGARDING GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently are not generating revenue from operations, and do not anticipate generating meaningful revenue from operations or otherwise in the short-term. We have historically financed our operations primarily through issuances of equity and the proceeds from the issuance of promissory notes. In the past, we also provided for our cash needs by issuing our common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_zpFnot3jc323" title="Common stock, par or stated value per share">0.01</span> per share (“Common Stock”), options and warrants for certain operating costs, including consulting and professional fees, as well as divesting its minority equity interests and equity-linked investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our history of operating losses, limited cash resources and the absence of an operating plan necessary to capitalize on our assets raise substantial doubt about our ability to continue as a going concern absent a strengthening of our cash position. Management is currently pursuing various funding options, including seeking debt or equity financing, licensing opportunities and the sale of certain investment holdings, as well as a strategic, merger or other transaction to obtain additional funding to continue the development of, and to successfully commercialize, our products. There can be no assurance that the Company will be successful in its efforts. Should we be unable to obtain adequate financing or generate sufficient revenue in the future, the Company’s business, result of operations, liquidity and financial condition would be materially and adversely harmed, and we will be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There can be no assurance that, assuming we are able to strengthen its cash position, we will achieve sufficient revenue or profitable operations to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.01 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zBCdhxh68D33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_828_zZv6vCVGKXG7">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to GAAP and have been consistently applied in the preparation of the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWWy1qi9Nbr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zQqr4ZYRBck">Accounting for Share-Based Payments</span>. </i>The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“Topic 718”),, which establishes the accounting for transactions in which an entity exchanges equity securities for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company uses the Black-Scholes option pricing model in determining fair value. Accordingly, compensation cost has been recognized using the fair value method and expected term accrual requirements as prescribed. During the three months ended March 31, 2022 and 2021, the Company had <span id="xdx_907_eus-gaap--ShareBasedCompensation_do_c20220101__20220331_zI3DABCbJIz4" title="Share based compensation expenses"><span id="xdx_909_eus-gaap--ShareBasedCompensation_do_c20210101__20210331_zwNL4Yhvt5Zf" title="Share based compensation expenses">no</span></span> stock compensation expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In June 2018, the FASB issued Accounting Standards Update (“<i>ASU</i>”) No. 2018-07, “<i>Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”</i> (“<i>2018-07</i>”) to expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted for an “emerging growth company” beginning after December 15, 2019. The Company has adopted this standard effective from January 1, 2020 and the adoption of this standard did not have any significant impact on the unaudited condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of modifications, the Black-Scholes model is used to value modified warrants on the modification date by applying the revised assumptions. The difference between the fair value of the warrants prior to the modification and after the modification determines the incremental value. In the past, the Company has modified warrants in connection with the issuance of certain notes and note extensions. These modified warrants were originally issued in connection with previous private placement investments. In the case of debt issuances, the warrants were accounted for as original issuance discount based on their relative fair values. When modified in connection with a note issuance, the Company recognizes the incremental value as a part of the debt discount calculation, using its relative fair value in accordance with ASC Topic 470-20, “<i>Debt with Conversion and Other Options</i>”. When modified in connection with note extensions, the Company recognized the incremental value as prepaid interest, which is expensed over the term of the extension.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each share-based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year. During the three months ended March 31, 2022 and 2021, the Company did not make any Black-Scholes model assumptions, as no share-based payments were made during those periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free Interest Rate.</i> The interest rate used is based on the yield of a U.S. Treasury security as of the beginning of the year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Volatility.</i> The Company calculates the expected volatility based on historical volatility of monthly stock prices over a three-year period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend Yield.</i> The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220331_z1B1ntzazxo7" title="Share-based payment, dividend rate">0%</span> dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Term.</i> For options, the Company has no history of employee exercise patterns. Therefore, the Company uses the option term as the expected term. For warrants, the Company uses the actual term of the warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Vesting Forfeitures.</i> Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMG8TNT6QzT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zwmykxotAw06">Earnings per Share</span>. </i>The Company computes net income (loss) per common share in accordance with ASC Topic 260, “<i>Earnings Per Share</i>” (“<i>Topic 260</i>”). Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. <span style="background-color: white">Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For the three months ended March 31, 2022 and the three months ended March 31, 2021, b</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">asic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and at March 31, 2021, the Company had outstanding warrants exercisable for <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqaYCAY7i7c" title="Outstanding warrants exercisable"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGCQVs8VNi57">15,000,000</span></span> shares of Common Stock, and outstanding preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztjjbxQOCRV1" title="Preferred stock, par or stated value per share"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbvOQ1OXhDGk">0.01</span></span> par value (“<i>Preferred Stock</i>”) convertible into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zG8h9lbD5Bia" title="Shares of preferred stock convertible"><span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGiB0adknxY" title="Shares of preferred stock convertible">6,196,893</span></span> shares of its Common Stock, which options, warrants and Preferred Stock were deemed to be antidilutive for the three months ended March 31, 2022 and March 31, 2021. At March 31, 2022 and March 31, 2021, the Company had reserved for issuance to certain investors <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zktu9ThWgcbh" title="Common stock reserved for issuance"><span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOu5vON1JUF3" title="Common stock reserved for issuance">860,000</span></span> shares of its Series B Convertible Preferred Stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmDdhALbC07b" title="Preferred stock, par or stated value per share"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPy0bbcDxt86" title="Preferred stock, par or stated value per share">0.01</span></span> per share (“<i>Series B Preferred</i>”), convertible into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmPPO3VCb268" title="Conversion of shares converted"><span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg8suZdtpP0a" title="Conversion of shares converted">860,000</span></span> shares of its Common Stock. As of March 31, 2022 and at March 31, 2021, the Company has estimated and reserved for issuance approximately <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn5n6_c20220331_zv3xbCDgZMh" title="Common stock reserved for issuance"><span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn5n6_c20210331_zv63pR9a0URa">20.0</span></span> million shares of Common Stock for a future conversion of its issued and outstanding Bridge Notes (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyWlqR3odoG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zqQGj1KGzpDf">Fair Value</span>. </i>The Company has adopted ASC Topic 820, “<i>Fair Value Measurements and Disclosures</i>” for both financial and nonfinancial assets and liabilities. The Company has not elected the fair value option for any of its assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zKcwYkRSW8p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zwnLbwZnTLEk">Use of Estimates</span>.</i> The accompanying financial statements are prepared in conformity with GAAP, and include certain estimates and assumptions, which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting period. Accordingly, actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--ReclassificationsPolicyTextBlock_zdRymcHZyByf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zTVXnmpfVKw2">Reclassifications</span>. </i>Prior period financial statement amounts have been reclassified to conform to current period presentation. The reclassifications have no effect on net loss or earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziK4D5WxsH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zSW0hOIYGQPk">Recent Accounting Pronouncements</span></i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has considered all recent accounting pronouncements in the current period and identified no pronouncements that would have an impact on our financial statements.</span></p> <p id="xdx_85A_zbL2BTsKvszl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84F_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWWy1qi9Nbr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zQqr4ZYRBck">Accounting for Share-Based Payments</span>. </i>The Company follows the provisions of Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“Topic 718”),, which establishes the accounting for transactions in which an entity exchanges equity securities for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company uses the Black-Scholes option pricing model in determining fair value. Accordingly, compensation cost has been recognized using the fair value method and expected term accrual requirements as prescribed. During the three months ended March 31, 2022 and 2021, the Company had <span id="xdx_907_eus-gaap--ShareBasedCompensation_do_c20220101__20220331_zI3DABCbJIz4" title="Share based compensation expenses"><span id="xdx_909_eus-gaap--ShareBasedCompensation_do_c20210101__20210331_zwNL4Yhvt5Zf" title="Share based compensation expenses">no</span></span> stock compensation expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In June 2018, the FASB issued Accounting Standards Update (“<i>ASU</i>”) No. 2018-07, “<i>Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”</i> (“<i>2018-07</i>”) to expand the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted for an “emerging growth company” beginning after December 15, 2019. The Company has adopted this standard effective from January 1, 2020 and the adoption of this standard did not have any significant impact on the unaudited condensed consolidated interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of modifications, the Black-Scholes model is used to value modified warrants on the modification date by applying the revised assumptions. The difference between the fair value of the warrants prior to the modification and after the modification determines the incremental value. In the past, the Company has modified warrants in connection with the issuance of certain notes and note extensions. These modified warrants were originally issued in connection with previous private placement investments. In the case of debt issuances, the warrants were accounted for as original issuance discount based on their relative fair values. When modified in connection with a note issuance, the Company recognizes the incremental value as a part of the debt discount calculation, using its relative fair value in accordance with ASC Topic 470-20, “<i>Debt with Conversion and Other Options</i>”. When modified in connection with note extensions, the Company recognized the incremental value as prepaid interest, which is expensed over the term of the extension.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each share-based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year. During the three months ended March 31, 2022 and 2021, the Company did not make any Black-Scholes model assumptions, as no share-based payments were made during those periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk-Free Interest Rate.</i> The interest rate used is based on the yield of a U.S. Treasury security as of the beginning of the year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Volatility.</i> The Company calculates the expected volatility based on historical volatility of monthly stock prices over a three-year period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividend Yield.</i> The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20220101__20220331_z1B1ntzazxo7" title="Share-based payment, dividend rate">0%</span> dividend yield.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expected Term.</i> For options, the Company has no history of employee exercise patterns. Therefore, the Company uses the option term as the expected term. For warrants, the Company uses the actual term of the warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pre-Vesting Forfeitures.</i> Estimates of pre-vesting option forfeitures are based on Company experience. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 0 <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zMG8TNT6QzT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zwmykxotAw06">Earnings per Share</span>. </i>The Company computes net income (loss) per common share in accordance with ASC Topic 260, “<i>Earnings Per Share</i>” (“<i>Topic 260</i>”). Net income (loss) per share is based upon the weighted average number of outstanding common shares and the dilutive effect of common share equivalents, such as options and warrants to purchase common stock, convertible preferred stock and convertible notes, if applicable, that are outstanding each year. <span style="background-color: white">Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For the three months ended March 31, 2022 and the three months ended March 31, 2021, b</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">asic and diluted earnings per share were the same at the reporting dates of the accompanying financial statements, as including common stock equivalents in the calculation of diluted earnings per share would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and at March 31, 2021, the Company had outstanding warrants exercisable for <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqaYCAY7i7c" title="Outstanding warrants exercisable"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGCQVs8VNi57">15,000,000</span></span> shares of Common Stock, and outstanding preferred stock, $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_ztjjbxQOCRV1" title="Preferred stock, par or stated value per share"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zbvOQ1OXhDGk">0.01</span></span> par value (“<i>Preferred Stock</i>”) convertible into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zG8h9lbD5Bia" title="Shares of preferred stock convertible"><span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zGiB0adknxY" title="Shares of preferred stock convertible">6,196,893</span></span> shares of its Common Stock, which options, warrants and Preferred Stock were deemed to be antidilutive for the three months ended March 31, 2022 and March 31, 2021. At March 31, 2022 and March 31, 2021, the Company had reserved for issuance to certain investors <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zktu9ThWgcbh" title="Common stock reserved for issuance"><span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zOu5vON1JUF3" title="Common stock reserved for issuance">860,000</span></span> shares of its Series B Convertible Preferred Stock, par value $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zmDdhALbC07b" title="Preferred stock, par or stated value per share"><span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zPy0bbcDxt86" title="Preferred stock, par or stated value per share">0.01</span></span> per share (“<i>Series B Preferred</i>”), convertible into <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmPPO3VCb268" title="Conversion of shares converted"><span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg8suZdtpP0a" title="Conversion of shares converted">860,000</span></span> shares of its Common Stock. As of March 31, 2022 and at March 31, 2021, the Company has estimated and reserved for issuance approximately <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn5n6_c20220331_zv3xbCDgZMh" title="Common stock reserved for issuance"><span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pn5n6_c20210331_zv63pR9a0URa">20.0</span></span> million shares of Common Stock for a future conversion of its issued and outstanding Bridge Notes (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> 15000000 15000000 0.01 0.01 6196893 6196893 860000 860000 0.01 0.01 860000 860000 20000000.0 20000000.0 <p id="xdx_84B_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zyWlqR3odoG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zqQGj1KGzpDf">Fair Value</span>. </i>The Company has adopted ASC Topic 820, “<i>Fair Value Measurements and Disclosures</i>” for both financial and nonfinancial assets and liabilities. The Company has not elected the fair value option for any of its assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zKcwYkRSW8p1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zwnLbwZnTLEk">Use of Estimates</span>.</i> The accompanying financial statements are prepared in conformity with GAAP, and include certain estimates and assumptions, which affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting period. Accordingly, actual results may differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--ReclassificationsPolicyTextBlock_zdRymcHZyByf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zTVXnmpfVKw2">Reclassifications</span>. </i>Prior period financial statement amounts have been reclassified to conform to current period presentation. The reclassifications have no effect on net loss or earnings per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ziK4D5WxsH3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zSW0hOIYGQPk">Recent Accounting Pronouncements</span></i>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has considered all recent accounting pronouncements in the current period and identified no pronouncements that would have an impact on our financial statements.</span></p> <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zHdW1kr2hQR2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_82B_z7HJMyPgRtT8">CONVERTIBLE NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years 2014 to 2017, the Company issued a series of Bridge Notes (the “<i>Bridge Notes</i>”) in aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20140101__20171231__us-gaap--DebtInstrumentAxis__custom--DateRangesMember_zQU8XObLjIW4" title="Aggregate principal amount">1,489,694</span>. The Bridge Notes matured on various dates through 2018. The Bridge Notes are in default and bear interest rates ranging from <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20171231__srt--RangeAxis__srt--MinimumMember_zmZzIq6LZyW2" title="Interest rate">12</span>% to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20171231__srt--RangeAxis__srt--MaximumMember_z0JL2b5C69Il" title="Interest rate">18</span>%. As of March 31, 2022, the Bridge Notes are due and payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ConvertibleDebtTableTextBlock_zjED3yL1Y562" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022 and December 31, 2021, the Company’s Convertible Notes Payable are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zkwVtyvKDcx5" style="display: none">SCHEDULE OF CONVERTIBLE NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20220331_zTYig0SaNKR2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20211231_zcDeTTbpeSzk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_maNPzE0W_zHEY4a9xFa15" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Notes Payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,387,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,387,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maNPzE0W_zfrdooj0lyX3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,117,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,067,644</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_maNPzE0W_zc99TGPGNyH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes Payable, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InterestPayableRelatedPartiesCurrent_iI_maNPzE0W_z5baE1G2sVfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued Interest, related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">83,289</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">79,490</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iTI_mtNPzE0W_z1ViZOkj5fud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Notes Payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,690,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zTrJ4ekPhmAl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable, Related Party.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $<span id="xdx_90E_ecustom--NotesPayableRelatedPartyAndAccruedInterestCurrent_iI_c20220331__srt--TitleOfIndividualAxis__custom--MrAbramsMember_zOuo7jfLn4u3" title="Notes payable, related party and accrued interest">185,289</span> and $<span id="xdx_900_ecustom--NotesPayableRelatedPartyAndAccruedInterestCurrent_iI_c20211231__srt--TitleOfIndividualAxis__custom--MrAbramsMember_zErVdSXSqKqe" title="Notes payable, related party and accrued interest">181,490</span>, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes. The Bridge Notes held by Mr. Abrams are in default and bear interest rates ranging from <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220331__srt--TitleOfIndividualAxis__custom--MrAbramsMember__srt--RangeAxis__srt--MinimumMember_zQ59hHYmzRDb" title="Interest rate">12</span>% to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220331__srt--TitleOfIndividualAxis__custom--MrAbramsMember__srt--RangeAxis__srt--MaximumMember_zNYa5Fqcj3U4" title="Interest rate">18</span>%. As of March 31, 2022, the Bridge Notes are due and payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1489694 0.12 0.18 <p id="xdx_896_eus-gaap--ConvertibleDebtTableTextBlock_zjED3yL1Y562" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022 and December 31, 2021, the Company’s Convertible Notes Payable are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zkwVtyvKDcx5" style="display: none">SCHEDULE OF CONVERTIBLE NOTES PAYABLE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20220331_zTYig0SaNKR2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20211231_zcDeTTbpeSzk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableCurrent_iI_maNPzE0W_zHEY4a9xFa15" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Notes Payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,387,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,387,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maNPzE0W_zfrdooj0lyX3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,117,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,067,644</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_maNPzE0W_zc99TGPGNyH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes Payable, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--InterestPayableRelatedPartiesCurrent_iI_maNPzE0W_z5baE1G2sVfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued Interest, related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">83,289</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">79,490</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayable_iTI_mtNPzE0W_z1ViZOkj5fud" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Notes Payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,690,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,636,828</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1387694 1387694 1117726 1067644 102000 102000 83289 79490 2690709 2636828 185289 181490 0.12 0.18 <p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zRlfXFX4f3Y6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_823_zEbRGOMkKYX4">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In November 2018, the Company authorized payment of $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20181101__20181130__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zNN6G5r3ocOg" title="Officers compensation">3,500</span> per month to Dr. Hirschman for his services as Chief Executive Officer and $<span id="xdx_908_eus-gaap--OfficersCompensation_c20181101__20181130__srt--TitleOfIndividualAxis__srt--DirectorMember_zc4iItxyR1me" title="Officers compensation">3,500</span> to Mr. Abrams for his services as a Director. Effective January 1, 2020, Mr. Abrams has waived the payments of fees for his services. Effective April 1, 2020, Dr. Hirschman has waived the payment of is fees as Chief Executive Officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $<span id="xdx_907_ecustom--NotesPayableRelatedPartyAndAccruedInterestCurrent_iI_pp0p0_c20220331_znarU6OCfXz5" title="Notes payable, related party and accrued interest">185,289</span> and $<span id="xdx_90C_ecustom--NotesPayableRelatedPartyAndAccruedInterestCurrent_iI_pp0p0_c20211231_zeH8rUWzo6Za" title="Notes payable, related party and accrued interest">181,490</span>, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 3500 3500 185289 181490 <p id="xdx_807_eus-gaap--PreferredStockTextBlock_zgZmJbUhAolf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_821_zp1gajdl2Ny2">PREFERRED STOCK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_zqAVOY9bB8Sk" title="Preferred stock, shares authorized">25,000,000</span> shares of Preferred Stock, of which <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zTekAUnOm4d2" title="Preferred stock, shares authorized">20,500,000</span> are designated as Series B Preferred, with a stated value of approximately $<span id="xdx_909_eus-gaap--CapitalUnits_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbosVAnJfD0i" title="Capital units, value">204,000</span> (“<i>Series B Preferred</i>”). The remaining authorized shares of Preferred Stock had not been designated by the Company as of March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Preferred ranks senior to the Company’s Common Stock for purposes of liquidation preference, and to all other classes and series of equity securities of the Company that by their terms did not rank senior to the Series B Preferred (“<i>Junior Stock</i>”). Holders of the Series B Preferred are entitled to receive cash dividends, when, as and if declared by the Board of Directors, and they shall be entitled to receive an amount equal to the cash dividend declared on one share of Common Stock multiplied by the number of shares of Common Stock equal to the outstanding shares of Series B Preferred, on an as converted basis. The holders of Series B Preferred have voting rights to vote as a class on matters (a) amending, altering or repealing the provisions of the Series B Preferred so as to adversely affect any right, preference, privilege or voting power of the Series B Preferred; or (b) to affect any distribution with respect to Junior Stock. At any time, the holders of Series B Preferred may, subject to limitations, elect to convert all or any portion of their Series B Preferred into fully paid non-assessable shares of <span id="xdx_90B_eus-gaap--DebtConversionDescription_c20220101__20220331_zp9atAh1Mpqj" title="Debt conversion, description">the Company’s Common Stock at a 1:1 conversion rate</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July and August, 2017, the Company entered into Note Purchase Agreements with two existing stockholders, pursuant to which the Company issued certain Bridge Notes (the “<i>2017 Bridge Notes</i>”) in the aggregate principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20170701__20170831__us-gaap--DebtInstrumentAxis__custom--BridgeNotesTwoZeroOneSevenMember_z9wPSuAWbdf" title="Debt instrument, periodic payment, principal">86,000</span>. As additional consideration for the purchase of the 2017 Bridge Notes, the Company has reserved for issuance an aggregate of <span id="xdx_907_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_c20170831__us-gaap--DebtInstrumentAxis__custom--BridgeNotesTwoZeroOneSevenMember_z6fXqngW4xv4" title="Preferred stock, capital shares reserved for future issuance">860,000</span> shares of Series B Preferred to be issued to the purchasers of the 2017 Bridge Notes. The Company has valued the Series B Preferred and has recorded a discount on the 2017 Bridge Notes of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20170101__20171231__us-gaap--DebtInstrumentAxis__custom--BridgeNotesTwoZeroOneSevenMember_zReH8HCJ1pm8" title="Amortization of debt discount premium">7,818</span>, which was amortized in full during the year ended December 31, 2017.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2018, the Company completed the purchase of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20180401__20180430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZSlMo7vCw79" title="Stock issued shares for purchase of assets">10,480,049</span> shares of Series B Preferred from an institutional shareholder for an aggregate purchase price of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20180401__20180430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbDUgpdzVPC5" title="Aggregate purchase price">20,000</span>. Following this transaction, the shareholder no longer holds shares in the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, the Company had <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFEK5Yq5Fyuc" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvDFwbvZUyUh" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9KRLd5vgTL2" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1vAegSifzS" title="Preferred stock, shares outstanding">6,196,893</span></span></span></span> shares of Series B Preferred issued and outstanding, with a liquidation preference of $<span id="xdx_90A_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWDNp1t1Q89h" title="Preferred stock, liquidation preference, value"><span id="xdx_900_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNjGdm2O2I9j" title="Preferred stock, liquidation preference, value">61,969</span></span> and convertible into <span id="xdx_904_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8bcyp6pX8hl" title="Preferred stock convertible shares of common stock"><span id="xdx_900_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYcahUKQWate" title="Preferred stock convertible shares of common stock">6,196,893</span></span> shares of the Company’s Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25000000 20500000 204000 the Company’s Common Stock at a 1:1 conversion rate 86000 860000 7818 10480049 20000 6196893 6196893 6196893 6196893 61969 61969 6196893 6196893 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zqQD4in1ber8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_822_zCLZYd0Djcge">COMMON STOCK, OPTIONS AND WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_zKBxilRfvf2g" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zgdOIrYuwXW7" title="Common stock, shares authorized">150,000,000</span></span> shares of its Common Stock for issuance, of which <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20220331_zaa9SDoD4Jc3" title="Common stock, shares, issued"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20211231_zlnvl08Vv0we" title="Common stock, shares, issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zozefB8fxAa1" title="Common stock, shares, outstanding"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zT47CozaXKVh" title="Common stock, shares, outstanding">78,696,461</span></span></span></span> were issued and outstanding at each March 31, 2022 and December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2022 and March 31, 2021, there were no warrants issued by the Company. As of March 31, 2022, the Company has one warrant issued and outstanding, this warrant was issued in December 2018 to Preprogen’s designee to purchase up to <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn5n6_c20220331_zBUmIURCwN0d" title="Warrants to purchase of common stock">15.0</span> million shares of the Company’s Common Stock, at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220331_zVfqTnxsIdj" title="Warrants exercise price per share">0.05</span> per share. The warrant was exercisable immediately upon issuance, and expires on <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220331_zHF6UPQzozIb" title="Warrants maturity date">December 14, 2022</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2007 Incentive and Non-Qualified Stock Option Plan. </i>The fair value of options granted under the Company’s 2007 Incentive and Non-Qualified Stock Option Plan is recorded as compensation expense over the vesting period, or, for performance based awards, the expected service term. <span style="background-color: white">The Company did not issue any options during the three months ended March 31, 2022 or 2021. As of March 31, 2022, the Company has <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_do_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5SOuCpCXyL4" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_pid_do_c20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z2yNRocFMsLd" title="Common stock, shares outstanding">no</span></span> options issued and outstanding.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 150000000 150000000 78696461 78696461 78696461 78696461 15000000.0 0.05 2022-12-14 0 0 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z4fTIivW15Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_82C_ztonLz1xzBTl">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2022, the Company received a shareholder loan in the amount of $<span id="xdx_904_eus-gaap--ProceedsFromRelatedPartyDebt_c20220411__20220412__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7zWcXJIwTyl" title="Proceeds from shareholder loan">25,000</span>.</span></p> 25000 EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 58 110 1 false 17 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://quantrxbiomedical.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://quantrxbiomedical.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://quantrxbiomedical.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://quantrxbiomedical.com/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://quantrxbiomedical.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Statements of Stockholders' Equity (Unaudited) Sheet http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Sheet http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentation DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN Sheet http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcern MANAGEMENT STATEMENT REGARDING GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://quantrxbiomedical.com/role/ConvertibleNotesPayable CONVERTIBLE NOTES PAYABLE Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://quantrxbiomedical.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - PREFERRED STOCK Sheet http://quantrxbiomedical.com/role/PreferredStock PREFERRED STOCK Notes 12 false false R13.htm 00000013 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS Sheet http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrants COMMON STOCK, OPTIONS AND WARRANTS Notes 13 false false R14.htm 00000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://quantrxbiomedical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables) Notes http://quantrxbiomedical.com/role/ConvertibleNotesPayableTables CONVERTIBLE NOTES PAYABLE (Tables) Tables http://quantrxbiomedical.com/role/ConvertibleNotesPayable 16 false false R17.htm 00000017 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Sheet http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) Details http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentation 17 false false R18.htm 00000018 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative) Sheet http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcernDetailsNarrative MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative) Details http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcern 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) Notes http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) Details 20 false false R21.htm 00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://quantrxbiomedical.com/role/ConvertibleNotesPayableTables 21 false false R22.htm 00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://quantrxbiomedical.com/role/RelatedPartyTransactions 22 false false R23.htm 00000023 - Disclosure - PREFERRED STOCK (Details Narrative) Sheet http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative PREFERRED STOCK (Details Narrative) Details http://quantrxbiomedical.com/role/PreferredStock 23 false false R24.htm 00000024 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative) Sheet http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative) Details http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrants 24 false false R25.htm 00000025 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://quantrxbiomedical.com/role/SubsequentEvents 25 false false All Reports Book All Reports form10-q.htm ex31.htm ex32.htm qtxb-20220331.xsd qtxb-20220331_cal.xml qtxb-20220331_def.xml qtxb-20220331_lab.xml qtxb-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 40 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 58, "dts": { "calculationLink": { "local": [ "qtxb-20220331_cal.xml" ] }, "definitionLink": { "local": [ "qtxb-20220331_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "qtxb-20220331_lab.xml" ] }, "presentationLink": { "local": [ "qtxb-20220331_pre.xml" ] }, "schema": { "local": [ "qtxb-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 209, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 23, "http://xbrl.sec.gov/dei/2022": 4, "total": 27 }, "keyCustom": 4, "keyStandard": 106, "memberCustom": 5, "memberStandard": 12, "nsprefix": "QTXB", "nsuri": "http://quantrxbiomedical.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://quantrxbiomedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - CONVERTIBLE NOTES PAYABLE", "role": "http://quantrxbiomedical.com/role/ConvertibleNotesPayable", "shortName": "CONVERTIBLE NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://quantrxbiomedical.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - PREFERRED STOCK", "role": "http://quantrxbiomedical.com/role/PreferredStock", "shortName": "PREFERRED STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS", "role": "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrants", "shortName": "COMMON STOCK, OPTIONS AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS", "role": "http://quantrxbiomedical.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - CONVERTIBLE NOTES PAYABLE (Tables)", "role": "http://quantrxbiomedical.com/role/ConvertibleNotesPayableTables", "shortName": "CONVERTIBLE NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)", "role": "http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationDateOfIncorporation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative)", "role": "http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcernDetailsNarrative", "shortName": "MANAGEMENT STATEMENT REGARDING GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "role": "http://quantrxbiomedical.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:NotesPayableCurrent", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details)", "role": "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails", "shortName": "SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayableRelatedPartiesClassifiedCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "QTXB:NotesPayableRelatedPartyAndAccruedInterestCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)", "role": "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "shortName": "CONVERTIBLE NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31_custom_MrAbramsMember", "decimals": "0", "lang": null, "name": "QTXB:NotesPayableRelatedPartyAndAccruedInterestCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "QTXB:NotesPayableRelatedPartyAndAccruedInterestCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2018-11-012018-11-30_srt_ChiefExecutiveOfficerMember", "decimals": "0", "lang": null, "name": "us-gaap:OfficersCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - PREFERRED STOCK (Details Narrative)", "role": "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative", "shortName": "PREFERRED STOCK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtConversionDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative)", "role": "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative", "shortName": "COMMON STOCK, OPTIONS AND WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "-5", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-112022-04-12_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-04-112022-04-12_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "role": "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations (Unaudited)", "role": "http://quantrxbiomedical.com/role/StatementsOfOperations", "shortName": "Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://quantrxbiomedical.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Stockholders' Equity (Unaudited)", "role": "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "shortName": "Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentation", "shortName": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - MANAGEMENT STATEMENT REGARDING GOING CONCERN", "role": "http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcern", "shortName": "MANAGEMENT STATEMENT REGARDING GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 17, "tag": { "QTXB_BridgeNotesTwoZeroOneSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bridge Notes 2017 [Member]", "label": "Bridge Notes 2017 [Member]" } } }, "localname": "BridgeNotesTwoZeroOneSevenMember", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "QTXB_DateRangesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date Ranges [Member]", "label": "Date Ranges [Member]" } } }, "localname": "DateRangesMember", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "QTXB_InterestPayableRelatedPartiesCurrent": { "auth_ref": [], "calculation": { "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails": { "order": 4.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest, related party, current.", "label": "Accrued Interest, related Party" } } }, "localname": "InterestPayableRelatedPartiesCurrent", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "QTXB_MrAbramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Abrams [Member]", "label": "Mr. Abrams [Member]" } } }, "localname": "MrAbramsMember", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "QTXB_NotesPayableRelatedPartyAndAccruedInterestCurrent": { "auth_ref": [], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes payable related party and accrued interest current.", "label": "Notes Payable, related party and accrued interest", "verboseLabel": "Notes payable, related party and accrued interest" } } }, "localname": "NotesPayableRelatedPartyAndAccruedInterestCurrent", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets", "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "QTXB_ReclassificationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassifications [Policy Text Block]", "label": "Reclassifications" } } }, "localname": "ReclassificationsPolicyTextBlock", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "QTXB_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "QTXB_StockToBeIssued": { "auth_ref": [], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock to be issued.", "label": "Stock to be issued" } } }, "localname": "StockToBeIssued", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "QTXB_StockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock to be Issued [Member]", "label": "Stock to be Issued [Member]" } } }, "localname": "StockToBeIssuedMember", "nsuri": "http://quantrxbiomedical.com/20220331", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r318", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Date of incorporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "verboseLabel": "State of incorporation" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover", "http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://quantrxbiomedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r125", "r126", "r127", "r128", "r143", "r178", "r204", "r205", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r295", "r296", "r305", "r306" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r125", "r126", "r127", "r128", "r143", "r178", "r204", "r205", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r295", "r296", "r305", "r306" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r143", "r178", "r203", "r204", "r205", "r212", "r213", "r214", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r295", "r296", "r305", "r306" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r143", "r178", "r203", "r204", "r205", "r212", "r213", "r214", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r295", "r296", "r305", "r306" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r120", "r257" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r21", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r73", "r74", "r75", "r216", "r217", "r218", "r235" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r47", "r55", "r163", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount premium" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r7", "r68", "r112", "r114", "r118", "r122", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r226", "r228", "r239", "r260", "r262", "r275", "r286" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r19", "r68", "r122", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r226", "r228", "r239", "r260", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r72", "r109" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/DescriptionOfBusinessAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalUnits": { "auth_ref": [ "r302" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital units, value" } } }, "localname": "CapitalUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r6", "r57" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r51", "r57", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r51", "r240" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Net Decrease in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r11", "r12", "r13", "r65", "r68", "r87", "r88", "r89", "r91", "r93", "r99", "r100", "r101", "r122", "r129", "r133", "r134", "r135", "r138", "r139", "r175", "r176", "r181", "r185", "r192", "r239", "r323" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r279", "r290" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common stock reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r73", "r74", "r235" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock, par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcernDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r192" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.01 par value; 150,000,000 authorized; 78,696,461 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r59", "r60", "r61" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "SCHEDULE OF CONVERTIBLE NOTES PAYABLE" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r45" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total Costs and Operating Expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Operating Expense:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r64", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r157", "r164", "r165", "r166", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "CONVERTIBLE NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r67", "r71", "r140", "r141", "r142", "r143", "r144", "r145", "r147", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r163", "r167", "r168", "r169", "r170", "r251", "r276", "r277", "r285" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26", "r141" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r27", "r67", "r71", "r140", "r141", "r142", "r143", "r144", "r145", "r147", "r153", "r154", "r155", "r156", "r158", "r159", "r160", "r161", "r162", "r163", "r167", "r168", "r169", "r170", "r251" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Aggregate principal amount", "verboseLabel": "Debt instrument, periodic payment, principal" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r34", "r230", "r231", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r43", "r78", "r79", "r80", "r81", "r82", "r86", "r87", "r91", "r92", "r93", "r96", "r97", "r236", "r237", "r282", "r292" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and Diluted Net Loss per Common Share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r37", "r38", "r39", "r73", "r74", "r75", "r77", "r83", "r85", "r98", "r123", "r192", "r199", "r216", "r217", "r218", "r222", "r223", "r235", "r241", "r242", "r243", "r244", "r245", "r246", "r252", "r297", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r41", "r112", "r113", "r116", "r117", "r119", "r274", "r280", "r284", "r293" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Profit (Loss) Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r69", "r84", "r85", "r111", "r221", "r224", "r225", "r294" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for Income Taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income tax paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r54" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r54" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r40", "r110", "r248", "r250", "r283" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r50", "r52", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails": { "order": 2.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, accrued interest", "verboseLabel": "Accrued Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets", "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r68", "r115", "r122", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r227", "r228", "r229", "r239", "r260", "r261" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r68", "r122", "r239", "r262", "r278", "r289" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided (Used) by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r53", "r56" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r35", "r36", "r39", "r42", "r56", "r68", "r76", "r78", "r79", "r80", "r81", "r84", "r85", "r90", "r112", "r113", "r116", "r117", "r119", "r122", "r129", "r130", "r131", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r237", "r239", "r281", "r291" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Profit (Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows", "http://quantrxbiomedical.com/role/StatementsOfOperations", "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r10", "r277", "r287" ], "calculation": { "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable [Default Label]", "totalLabel": "Total Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails": { "order": 1.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets", "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r20", "r70", "r256" ], "calculation": { "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails": { "order": 3.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ScheduleOfConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Officers compensation" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r112", "r113", "r116", "r117", "r119" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS:" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total Other Income (Expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance.", "label": "Preferred stock, capital shares reserved for future issuance" } } }, "localname": "PreferredStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred stock convertible shares of common stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r65", "r181" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation preference, value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r175" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r175" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "PREFERRED STOCK" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock; $0.01 par value, 25,000,000 authorized shares; 20,500,000 shares designated as Series B Convertible Preferred Stock; Series B Convertible Preferred shares 6,196,893 issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from shareholder loan" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r303", "r304" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r253", "r254", "r255", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r199", "r262", "r288", "r300", "r301" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r73", "r74", "r75", "r77", "r83", "r85", "r123", "r216", "r217", "r218", "r222", "r223", "r235", "r297", "r299" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r11", "r12", "r13", "r65", "r99", "r100", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r181", "r185", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://quantrxbiomedical.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r11", "r12", "r192" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based payment, dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r207", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Outstanding warrants exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r206", "r209", "r210", "r211", "r212", "r215", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Accounting for Share-Based Payments" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ConvertibleNotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63", "r72" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r65", "r68", "r87", "r88", "r89", "r91", "r93", "r99", "r100", "r101", "r122", "r129", "r133", "r134", "r135", "r138", "r139", "r175", "r176", "r181", "r185", "r192", "r239", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r37", "r38", "r39", "r73", "r74", "r75", "r77", "r83", "r85", "r98", "r123", "r192", "r199", "r216", "r217", "r218", "r222", "r223", "r235", "r241", "r242", "r243", "r244", "r245", "r246", "r252", "r297", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r73", "r74", "r75", "r98", "r273" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheetsParenthetical", "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity", "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock issued shares for purchase of assets" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r68", "r121", "r122", "r239", "r262" ], "calculation": { "http://quantrxbiomedical.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets", "http://quantrxbiomedical.com/role/StatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r66", "r176", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r199", "r200", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "COMMON STOCK, OPTIONS AND WARRANTS" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r247", "r264" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r247", "r264" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r247", "r264" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r247", "r264" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r263", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "MANAGEMENT STATEMENT REGARDING GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/ManagementStatementRegardingGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r102", "r103", "r104", "r105", "r106", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants maturity date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/CommonStockOptionsAndWarrantsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r86", "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and Diluted Weighted Average Shares Used in per Share Calculation" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://quantrxbiomedical.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r308": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r309": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r311": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r312": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r313": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r314": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r315": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r316": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r317": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r318": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r319": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r320": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r321": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r322": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r323": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r324": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r325": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r326": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r327": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" } }, "version": "2.1" } ZIP 41 0001493152-22-013802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-013802-xbrl.zip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�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end